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Expression of a heterologous protein C in mammary tissue of transgenic
animals using a long whey acidic protein promoter
Abstract
An isolated DNA sequence which regulates the expression of a heterologous gene
composed of a mouse whey acidic protein promoter having a length of greater than about
2.4 kb extending upstream from the unique KpnI site in the mouse whey acidic protein
gene is disclosed. Specifically a mouse whey acidic protein promoter of about 4.1-4.2 kb
in length extending upstream from the unique KpnI site is preferred. This mouse whey
acid protein promoter is operably linked to a DNA sequence encoding a heterologous
polypeptide and used to prepare transgenic non-human mammals expressing the
heterologous polypeptide in their milk. Particularly efficient expression of both cDNAs
and genomic DNAs encoding heterologous polypeptides was obtained in transgenic nonhuman mammals using this promoter, known as the long whey acidic protein promoter.
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Claims

What we claim is:
1. An isolated DNA sequence which regulates the expression of a heterologous gene,
wherein the DNA sequence comprises a mouse whey acidic protein promoter having a
length of greater than about the length of the EcoRI-KpnI promoter of the mouse whey
acidic protein gene.
2. An isolated DNA sequence according to claim 1, wherein the DNA sequence
comprises a mouse whey acidic protein promoter having a length of greater than about
the length of the EcoRI-KpnI promoter of the mouse whey acidic protein gene to less
than about the length of the Sau3A-KpnI promoter of the mouse whey acidic protein
gene.
3. An isolated DNA sequence according to claim 2, wherein the DNA sequence has
functionally equivalent promoter activity to the mouse whey acidic protein 4.2 kb Sau3AKpnI promoter.
4. An isolated DNA sequence according to claim 1 comprising at least the approximately
4.2 kb Sau3A-KpnI promoter.
5. An isolated DNA sequence according to claim 1 comprising at least the NotI-KpnI
promoter of the mouse whey acidic protein gene.
6. An isolated DNA sequence according to claim 1, operably linked to a DNA sequence
encoding a heterologous polypeptide and a 3'-untranslated region from a mammary
gland-specific gene or 3'-untranslated region active in a mammary gland.
7. An isolated DNA sequence according to claim 6, wherein said 3'-untranslated region is
the 1.6 kb fragment of the mouse whey acidic protein gene.
8. A transgenic non-human mammal containing a DNA sequence stably integrated in its
genome, wherein said DNA sequence comprises a mouse whey acidic protein promoter
having a length of greater than about the length of the EcoRI-KpnI promoter of the
mouse whey acidic protein gene, operably linked to a DNA sequence encoding a
heterologous polypeptide, whereby said polypeptide is expressed specifically in
mammary cells of said transgenic mammal and said polypeptide comprises a signal
peptide, said signal peptide being effective in directing the secretion of said polypeptide
into the milk of said mammal.

9. The transgenic non-human mammal of claim 8, wherein said transgenic non-human
mammal is selected from the group consisting of mice, rats, rabbits, pigs, sheep, goats
and cows.
10. The transgenic non-human mammal of claim 9, wherein said mammal is a sheep.
11. The transgenic non-human mammal of claim 9, wherein said mammal is a goat.
12. The transgenic non-human mammal of claim 9, wherein said mammal is a cow.
13. The transgenic non-human mammal of claim 9, wherein said mammal is a pig.
14. The transgenic non-human mammal of claim 8, wherein said heterologous
polypeptide is a blood protein.
15. The transgenic non-human mammal of claim 14, wherein said blood protein is protein
C, Factor IX, fibrinogen or Factor VIII.
16. The transgenic non-human mammal of claim 8, wherein said heterologous
polypeptide is protein C, wherein the activated form of said secreted protein C has an
enzymatic activity of at least 50% as plasma-derived protein C, and wherein said
transgenic mammal is selected from the group consisting of mice, rats, rabbits, pigs,
sheep, goats and cows.
17. The transgenic non-human mammal of claim 16, wherein said DNA sequence
encoding the heterologous polypeptide comprises the human protein C gene from 21
basepairs upstream of the protein C start codon to the NheI site in the 3' end of the
protein C gene.
18. The transgenic non-human mammal of claim 8, wherein said DNA sequence
encoding said heterologous polypeptide further comprises regulatory elements located in
the non-coding regions of the heterologous protein gene, wherein said regulatory
elements are at least one of the AUG start codon, donor and acceptor splice signals, the
secretion peptide, translation termination signal, transcription termination signal, and
polyadenylation signal.
19. A process for the production of a heterologous polypeptide in the milk of a transgenic
non-human mammal, comprising the steps of:
(A) providing a transgenic non-human mammal whose genome comprises a stably
integrated DNA sequence comprising a mouse whey acidic promoter having a length of
greater than about the length of the EcoRI-KpnI promoter of the mouse whey acidic
protein gene, operably linked to a DNA sequence encoding a heterologous polypeptide
and a signal peptide, said promoter being specifically active in mammary cells and said
signal peptide being effective in directing the secretion of said polypeptide into the milk
of said transgenic mammal;

(B) producing milk from said transgenic mammal, wherein said milk contains said
polypeptide;
(C) collecting said milk; and
(D) isolating said polypeptide from said milk.
20. The process of claim 19, wherein said transgenic non-human mammal is selected
from the group consisting of mice, rats, rabbits, pigs, sheep, goats and cows.
21. The process of claim 20, wherein said transgenic non-human mammal is a sheep.
22. The process of claim 20, wherein said transgenic non-human mammal is a goat.
23. The process of claim 20, wherein said transgenic non-human mammal is a cow.
24. The mammal of claim 20, wherein said transgenic non-human mammal is a pig.
25. The process of claim 19, wherein said heterologous polypeptide is a blood protein.
26. The process of claim 25, wherein said blood protein is protein C, Factor IX,
fibrinogen or Factor VIII.
27. The process of claim 19, wherein said heterologous polypeptide is protein C, wherein
the activated form of said secreted protein C has an enzymatic activity of at least 50% as
plasma-derived protein C, and wherein said transgenic mammal is selected from the
group consisting of mice, rats, rabbits, pigs, sheep, goats and cows.
28. The process of claim 19, wherein said DNA sequence encoding the heterologous
polypeptide comprises the human protein C gene from 21 basepairs upstream of the
protein C start codon to the NheI site in the 3' end of the protein C gene.
29. The process of claim 19, wherein said DNA sequence encoding said heterologous
polypeptide further comprises regulatory elements located in the non-coding regions of
the heterologous protein gene, wherein said regulatory elements are at least one of the
AUG start codon, donor and acceptor splice signals, the secretion peptide, translation
termination signal, transcription termination signal, and polyadenylation signal.
Description

The present invention relates to an isolated DNA sequence which regulates the
expression of a heterologous gene comprising a mouse whey acidic protein (WAP)
promoter having a length of greater than about 2.4 kb extending upstream from the

unique KpnI site in the mouse whey acidic protein. The present invention also relates to a
transgenic non-human mammal containing a DNA sequence stably integrated in its
genome, wherein the DNA sequence contains the mouse whey acidic protein promoter
having a length of greater than about 2.4 kb extending upstream from the unique KpnI
site in the mouse whey acidic protein gene and is operably linked to a DNA sequence
encoding a heterologous polypeptide and a process of producing the heterologous
polypeptide in the milk of the transgenic mammal. The DNA sequence can comprise
cDNA or genomic DNA encoding the heterologous protein.
The present invention also relates to the production of natural and modified forms of the
human coagulation factor protein C. In particular, the invention relates to a transgenic
animal containing, stably incorporated in its genomic DNA, an exogenous gene which is
expressed in tissue of the animal, specifically in mammary tissue, such that protein C is
secreted into a body fluid of the animal, particularly into the milk produced by the
animal. In particular, the invention relates to the production of natural and modified
forms of protein C in the milk of a transgenic non-human mammal using a DNA
molecule that comprises, a mouse whey acid protein promoter having a length of greater
than about 2.4 kb extending upstream from the unique KpnI site in the mouse whey
acidic protein gene, particularly the upper range of this length, which is herein referred to
as the long whey acidic protein (WAP) promoter fragment and a cDNA or genomic DNA
encoding human protein C. The long whey acidic protein promoter fragment also can be
used to express high levels of other genes in cells, such as mammary cells of transgenic
non-human mammals.
BACKGROUND OF THE INVENTION
Protein C is an important component of the coagulation system that has strong
anticoagulant activity. In its active form it is a serine protease that proteolytically
inactivates Factors Va and VIIIa.
Human protein C (hPC) is a 62 kD, disulfide-linked heterodimer consisting of a 25 kD
light chain and a 41 kD heavy chain which circulates as an inactive zymogen in plasma.
At the endothelial cell surface it is activated to activated protein C (APC) by limited
thrombin proteolysis in the presence of thrombomodulin; cleavage of an Arg-Leu bond in
the amino terminal portion of the heavy chain releases a 12 amino acid peptide. See
generally Gardiner & Griffin in PROGRESS IN HEMATOLOGY, Vol. XIII at page 265278 (Brown, Grune and Stratton, Inc. 1983).
Several regions of the molecule have important implications for function as an
anticoagulant in the regulation of hemostasis. The amino terminal portion of the light
chain contains the nine y-carboxyglutamic acid (Gla) residues required for calciumdependent membrane binding and functional activation. Another post-translational
modification is .beta.-hydroxylation of aspartic acid reside 71, possibly required for
calcium-dependent membrane binding which is independent of the binding activity of the
Gla regions.

There are a variety of clinical situations for which protein C may prove beneficial. It may
serve as replacement therapy in homozygous deficient infants suffering from purpura
fulminans neonatalis. Other conditions include patients with a previous history of
warfarin-induced skin necrosis who must have additional warfarin therapy, heparininduced thrombocytopenia, septic shock for prevention of intravascular coagulation and
organ damage, and for fibrinolytic therapy, as protein C can protect tPA from plasma
inhibitor proteins. Table 1 represents one estimate of the number of individual cases of
several clinical syndromes which might be treated by purified protein C. Because there
has not been sufficient material available from plasma for clinical trials until recently,
these data are necessarily based on an incomplete assessment of the therapeutic potential
for protein C.
TABLE 1
PARTIAL ESTIMATE OF U.S. CLINICAL REQUIREMENTS
FOR PROTEIN C AND ACTIVATED PROTEIN C
Estimated
Dose (mg)
Per
# Treatments
Total U.S.
Indication
Treatment
Per Year
Req. (Kg)
Septic Shock
5-50
120,000
0.6-6.0
Thrombolytic
10-100
800,000
8-80
Therapy**
Hip Replacement
10-100
200,000
2-20
Homozygous
3
100 .times. 365*
0.10
Deficient
Heterozygous
50
1,000
0.05
Deficient
Total
10.8-106.2
*100 individuals in U.S. .times. 365 treatment/year
**Referes to the use of APC, following thrombolytic therapy, to
prevent the
reformation of blood clots.

The gene for human protein C has been cloned and sequenced, as has bovine protein C
gene. See Forster et al., Proc. Nat'l Acad. Sci. USA 82: 4673 (1985); U.S. Pat. No.
4,775,624. It is synthesized as an inactive precursor that undergoes several proteolytic
events during the processes of secretion and activation. First, a signal sequence as
proteolytically removed upon secretion. A second proteolytic event removes the
dipeptide lys156 arg157, producing the inactive zymogen, a two chain disulfide bridged
protein, consisting of a light chain of 155 amino acids and a heavy chain of 262 amino
acids. The zymogen is activated by a final proteolytic event that removes residues 158169, yielding active protein C, a serine protease with potent anticoagulant activity.
Beckmann et al., Nucleic Acids Res. 13: 5233 (1985).
In addition to proteolytic processing, human protein C undergoes several post-translation
modifications. Perhaps most salient among these modifications is the .gamma.carboxylation of the first nine glutamic acid residues in protein C, by a vitamin K
dependent enzyme. DiScipio & Davie, Biochemistry 18: 899 (1979). Gammacarboxylation is required for anticoagulant activity, and is associated with Ca.sup.2+ -

dependent membrane binding. The anticoagulant activity of protein C varies directly with
the extent of .gamma.-carboxylation, and the highest levels of activity are achieved only
when .gamma.-carboxylation of the sixth and seventh glutamic acid residues is effected.
Zhang & Castellino, Biochemistry 29: 10829 (1990).
Protein C is also post-translationally modified by .beta.-hydroxylation of aspartic acid 71.
Drakenberg et al., Proc. Nat'l Acad. Sci. USA 80: 1802 (1983). Beta-hydroxylation may
be important to protein C activity. Although its function is not known it has been
suggested that it may be involved in .gamma.-carboxyglutamic acid independent
Ca.sup.2+ binding, and it may be required for full anti-coagulant activity.
Human protein C is also glycosylated. Kisiel, J. Clin. Invest. 64: 761 (1979). It contains
four potential N-linked glycosylation sites, located at Asn97, Asn248, Asn313 and
Asn329. The first three signals match the consensus Asn-X-Ser/Thr glycosylation
sequences, and are actively glycosylated. There is an atypical glycosylation signal at
Asn329, Asn-X-Cys-Ser. The Asn329 signal is glycosylated in bovine protein C, but it is
not yet known if Asn329 is glycosylated in human protein C. Miletich et al., J. Biol.
Chem. 265: 11397 (1990). The pattern and extent of glycosylation can alter the
physiological activity of protein C.
Until recently, human protein C for experimental and therapeutic use was obtained
exclusively from human plasma. Unfortunately, the quantity of protein that can be
obtained from human serum is limited. Furthermore, products derived from human serum
pose difficulties of reliability, purity and safety.
The expression of therapeutic proteins by recombinant DNA technology is an attractive
alternative to plasma production of protein C, in that it eliminates the risk of potential
contamination with blood-borne viruses and theoretically provides an unlimited supply of
product. But the complexity of the post-translational modifications, as discussed above,
has rendered problematic the production of commercially useable amounts of suitably
active protein C by expression in a heterologous host.
In fact, it has not been possible to produce vitamin K-dependent proteins like protein C at
sufficiently high levels in an active form, despite efforts to do so using a variety of
expression systems. See Grinnell et al. in Volume 11 of ADVANCES IN APPLIED
BIOTECHNOLOGY SERIES, Chapter 3 (Gulf Publishing Co.). In particular, any
prospect for expressing protein C in mammary glands of a transgenic animal and
secreting the protein into milk, see, e.g., U.S. Pat. No. 4,873,316 (1989), is clouded by
the fact that protein C is normally synthesized in the liver. Even HepG2 cell lines derived
from human liver produce aberrant forms of protein C. Marlar & Fair (1985).
In this regard, it has been observed that a mouse mammary epithelial cell line (C-127)
transfected with a bovine papilloma virus (BPV) vector bearing the cDNA for human
protein C expressed protein C that was only 30-40% active. Further analysis revealed that
the protein C contained diminished levels of .gamma.-carboxyglutamic acid and little, if
any, .beta.-hydroxyaspartic acid. Suttie et al., Thrombosis Res. 44: 129 (1986). These

experiments indicate that mouse mammary epithelial cells cannot perform all of the posttranslational modifications necessary for obtaining suitably active protein C, which in
turn casts doubt on the likelihood of obtaining such protein C from the milk of a
transgenic mammal.
SUMMARY OF THE INVENTION
It is an object of the present invention to obtain and use an isolated DNA sequence which
regulates the expression of a heterologous gene, wherein the DNA sequence comprises of
a mouse whey acidic protein promoter having a length of greater than about 2.4 kb
extending upstream from the unique KpnI site in the mouse whey acidic protein gene.
The mouse whey acidic protein promoter of the present invention is more specifically an
isolated DNA sequence comprising a mouse whey acidic protein promoter having a
length of greater than about 2.4 kb to less than about 4.2 kb. The isolated DNA sequence
may also encompass mouse whey acidic protein promoters that are functionally
equivalent to the promoter activity of the mouse whey acidic 4.2 kb Sau3A-Kpn1
promoter.
It also is an object of the present invention to obtain and use an isolated DNA sequence
comprising a mouse whey acidic protein promoter comprising at least the approximately
mouse whey acidic protein 4.2 kb Sau3A-Kpn1 promoter.
It is a further object of the present invention to obtain and use an isolated DNA sequence
comprising a mouse whey acidic protein promoter comprising the NotI-Kpn1 promoter of
the mouse whey acidic protein gene.
It is an additional object of the present invention to operably link any of the disclosed
mouse whey acidic protein promoters to a DNA sequence encoding a heterologous
polypeptide and a 3'-untranslated region from a mammary gland-specific gene or a 3'untranslated region active in a mammary gland. This 3'-untranslated region is preferably
the 1.6 kb fragment of the mouse whey acidic protein gene. The DNA sequence encoding
a heterologous polypeptide is intended to be any DNA sequence that is known and
available to persons skilled in the art. The DNA sequence preferably encodes a blood
protein or plasma protein, and more preferably encodes such blood proteins as protein C,
Factor IX, fibrinogen, Factor VIII, thrombin, von Willebrand's factor, albumin, and
.alpha.1-antitrypsin, as well as growth factors and antibodies.
It also is an object of the present invention to produce a transgenic non-human mammal
containing a DNA sequence stably integrated in its genome, wherein the DNA sequence
comprises a mouse whey acidic protein promoter having a length of greater than about
2.4 kb extending upstream from the unique KpnI site in the mouse whey acidic protein
gene, operably linked to a DNA sequence encoding a heterologous polypeptide, whereby
the polypeptide is expressed specifically in mammary cells of the transgenic mammal and
the polypeptide comprises a signal peptide that is effective in directing the secretion of
the polypeptide into the milk of said mammal.

In a highly preferred embodiment the promoter comprises substantially the 5' 4.2 kb
Sau3A-Kpn1 promoter fragment of the mouse whey acidic protein gene, or a variant
thereof. This 4.2 kb Sau3A-KpnI promoter may be contained in a longer DNA sequence
to include polylinkers that will facilitate the construction of expression vectors, such as
for example, introducing a NotI cloning site upstream from the Sau3A site.
In another aspect in a preferred embodiment the DNA sequence encoding a polypeptide
having human protein C activity comprises portions of the non-coding regions of the
human protein C gene. In a particularly preferred embodiment, the DNA sequence gene
comprises substantially the human protein C gene from 21 basepairs upstream of the
protein C start codon to the NheI site in the 3' end of the protein C gene, or a variant
thereof is among the most highly preferred.
In a particularly preferred embodiment, the exogenous DNA sequence comprises a DNA
sequence consisting essentially of the 5' 4.2 kb Sau3A-Kpn1 promoter fragment of the
mouse whey acidic protein promoter ligated directly or by a linker to a fragment of the
human protein C gene beginning 21 basepairs upstream of the protein C start codon and
ending at the Nhel site in the 3' end of the protein C gene.
In accordance with another aspect of the present invention, there has been provided a
process for the production of protein C, comprising the steps of (A) providing a
transgenic mammal characterized by an exogenous DNA sequence stably integrated in its
genome, wherein the exogenous DNA sequence comprises a promoter operably linked to
a DNA sequence encoding a polypeptide having protein C activity and a signal peptide,
the promoter being specifically active in mammary cells and the signal peptide being
effective in directing the secretion of the protein C into the milk of the transgenic
mammal; (B) producing milk from the transgenic mammal; (C) collecting the milk; and
(D) isolating the polypeptide from the milk.
It is therefore an object of the present invention to provide a transgenic animal which
produces in its milk recombinant protein C that comprises a significantly higher
percentage of active protein than has been achieved heretofore.
It is another object of the present invention to provide a process for producing protein C
in commercially useable amounts, by means of a transgenic mammal.
In accomplishing the foregoing objects, there has been provided, in accordance with one
aspect of the present invention, a transgenic mammal containing an exogenous DNA
sequence stably integrated in its genome, wherein the exogenous DNA sequence
comprises a promoter operably linked to a DNA sequence encoding a polypeptide having
protein C activity and a signal peptide, wherein the promoter is specifically active in
mammary cells, particularly mammary epithelial cells, and the signal peptide is effective
in directing the secretion of the protein C into the milk of the transgenic mammal.
Additionally, in a preferred embodiment the DNA sequence encoding a polypeptide
having human protein C activity comprises portions of the non-coding regions of the

human protein C gene. In a particularly preferred embodiment of this type the DNA
sequence gene comprises substantially the human protein C gene from 21 basepairs
upstream of the protein C start codon to the NheI site in the 3' end of the protein C gene,
or a variant thereof is among the most highly preferred.
In addition, is certain a particularly preferred embodiment, the exogenous DNA sequence
comprises a DNA sequence consisting essentially of the 5' 4.2 kb Sau3A-Kpn1 promoter
fragment of the mouse whey acidic protein promoter ligated directly or by a linker to a
fragment of the human protein C gene beginning 21 basepairs upstream of the protein C
start codon and ending at the NheI site in the 3' end of the protein C gene.
In accordance with still another aspect of the present invention, a process has been
provided for producing transgenic animals, comprising the steps of (A) providing a
mixture containing a genetic construct; (B) subjecting the mixture to anion-exchange
high performance liquid chromatography to obtain purified genetic construct; and
thereafter (C) microinjecting an aqueous buffer solution containing the purified genetic
construct into an animal embryo. In a preferred embodiment, step (B) comprises applying
the mixture to an anion-exchange high performance liquid chromatography column,
eluting the genetic construct from the column, and then subjecting the genetic construct
to a second anion-exchange high performance liquid chromatography.
In a preferred embodiment of this aspect of the invention, the double-stranded DNA is
selected from the group consisting of a double-stranded DNA comprising substantially
the 5' 4.2 kb Sau3A-Kpn1 promoter fragment of the mouse whey acidic protein promoter,
a double-stranded DNA comprising substantially a fragment of the human protein C gene
beginning 21 basepairs upstream of the protein C start codon and ending at the NheI site
in the 3' end of the protein C gene, and a double-stranded DNA comprising a DNA
sequence consisting essentially of the 5' 4.2 kb Sau3A-Kpn1 promoter fragment of the
mouse whey acidic protein promoter ligated directly or by a linker to a fragment of the
human protein C gene beginning 21 basepairs upstream of the protein C start codon and
ending at the Nhel site in the 3' end of the protein C gene.
In accordance with yet another aspect of the invention, there has been provided a process
for the production of a polypeptide in the milk of a transgenic non-human mammal,
comprising the steps of providing a non-human transgenic mammal characterized by an
exogenous DNA sequence stably integrated in its genome, wherein said exogenous DNA
sequence comprises substantially the 5' 4.2 kb Sau3A-Kpn1 promoter of the mouse whey
acidic protein gene, or a variant thereof, operably linked to a DNA sequence encoding
said polypeptide and a signal peptide, said promoter being specifically active in
mammary cells and said signal peptide being effective in directing the secretion of said
polypeptide into the milk of said transgenic mammal; producing milk from said
transgenic mammal; collecting said milk; and isolating said polypeptide from said milk.
In a particularly preferred embodiment of this aspect of the invention, the exogenous
DNA sequence comprises the 5' 4.2 kb Sau3A-Kpn1 promoter fragment of the mouse
whey acidic protein promoter.

In accordance with yet another aspect of the invention there has been provided a
transgenic non-human mammal containing an exogenous DNA sequence stably
integrated in its genome, wherein the exogenous DNA sequence comprises substantially
the 4.2 kb Sau3A-Kpn1 whey acidic protein promoter fragment, or a variant thereof,
operably linked to a DNA encoding a polypeptide whereby the protein is expressed
specifically in mammary cells of the transgenic mammal and the protein comprises a
signal peptide, the peptide being effective in directing the secretion of the protein into the
milk of said mammal. In a particularly preferred embodiment of this aspect of the
invention, the exogenous DNA sequence comprises the 5' 4.2 kb Sau3A-Kpn1 promoter
fragment of the mouse whey acidic protein promoter.
In certain preferred embodiments of various aspects of the invention, the transgenic
mammal is mouse, rabbit, pig, sheep or goat. In some most highly preferred embodiments
the animal is pig or sheep.
Other objects, features and advantages of the present invention will become apparent
from the following detailed description. It should be understood, however, that the
detailed description and the specific examples, while indicating preferred embodiments
of the invention, are given by way of illustration only, since various changes and
modifications within the spirit and scope of the invention will become apparent to those
skilled in the art from this detailed description.
BRIEF DESCRIPTION OF THE FIGURES
FIG. 1 is a schematic diagram representing WAPpCI, a construct which contains cDNA
encoding human protein C inserted into an intact murine whey acidic protein (WAP)
gene at the unique Kpn1 site.
FIG. 2 is a schematic representation of polymerase chain reaction (PCR) primer pairs
useful to detect WAP-protein C DNAs in transgenic animals.
FIG. 3 is a graph that shows the results of an enzyme linked immunosorbent assay
(ELISA) of human protein C in milk obtained from a transgenic mouse.
FIG. 4 is a graph that shows the results of an APTT assay to determine human protein C
anti-coagulant activity in whey obtained from a transgenic mouse.
FIG. 5 is a graph that shows the results of Ca.sup.2+ -dependent and Ca.sup.2+ independent light chain capture ELISAs which demonstrate that the .gamma.carboxyglutamic acid in human protein C in whey from transgenic mouse Y52 is similar
to that in protein C derived from human serum.
FIG. 6 is a schematic diagram representing a highly preferred murine WAP-human
protein C construct. In this construct, a 4.2 kb 5' murine whey acidic protein promoter
fragment is linked to a 9.4 kb genomic fragment encoding human protein C which
includes the 400 bp extending from the end of exon VIII to the NheI site in the 3' end of

the human protein C gene. The sequence of the WAP--hPC junction is shown above the
schematic diagram.
FIG. 7 is a photograph showing the results of western analyses of human protein C
production in the milk of transgenic animals. Panel A shows the proteins in whey
samples resolved by PAGE under reducing conditions and visualized by silver staining.
Panel B shows the proteins detected by anti-human protein C antibodies in a western blot
of an identical gel, visualized by chemiluminescence. Lanes were loaded with
approximately 5 .mu.g of protein. Lanes 1 through 6 contained, respectively, samples
from transgenic mice 5.4, 6.4, 4.2.10, 5.2.12, 7.2.2 and 7.5.4. Lane 7 contained a sample
from a non-transgenic mouse. Lane 8 contained purified human protein C. "SC"--single
chain hPC, "HC"--heavy chain forms of hPC, "LC"--light chain hPC.
FIG. 8 shows the amidolytic activity in samples of whey from transgenic mice. Panel A
shows amidolytic activity of whey proteins resolved by PAGE under native conditions.
Panel B shows the proteins detected by anti-hPC antibodies in a western blot of an
identical gel, visualized using 4-chloro-1-naphthol. Lanes were loaded with
approximately 50 .mu.g of protein. Lane 1 contained purified human protein C. Lane 2
contained a sample form a non-transgenic mouse. Lanes 3 through 8 contained,
respectively, samples from transgenic mice 7.5.4, 7.2.2, 5.2.12, 4.2.10, 6.4 and 5.4.
FIG. 9 shows the nucleotide sequence SEQ ID NO:1 of the WAP gene promoter
fragment from the C57B/6 mouse strain. The sequence from the Sau3A site to the KpnI
site is shown.
FIGS. 10A-10D schematically depict the construction of a chimeric Factor IX (FIX)
construct containing the short WAP promoter. Specifically, FIG. 10A shows the
construction of pWAP4. FIG. 10B shows the production of pUCFIX. FIG. 10C shows the
introduction of human FIX cDNA into pWAP4. FIG. 10D shows the production of
pUCWAPFIX. FIX cDNA was modified by PCR in order to introduce KpnI sites on the
3' and 5' ends. Using FIX cDNA as a template, PCR primers humFIX5'KpnI and
humFIX3'KpnI, as shown in Table 6, below, were used to produce FIX cDNA with KpnI
sites on both ends. Modified cDNA may be easily introduced into a "cassette vector" for
constructing a chimeric gene.
FIGS. 11A-11C show the production of the pUCWAP6 "cassette vector." Specifically,
FIG. 11A shows the production of pUCNotI. FIG. 11B shows the production of of
pUCWAP5 and the production of a fragment that contains the pUCNotI vector sequence
flanked by mWAP3'UTR. FIG. 11C shows the production of pUCWAP6.
FIG. 12 shows the production of pUCWAP6FIX.
FIG. 13 shows the pUCWAP5 cassette vector containing the WAP fragment of
pUCWAP4 with added Not I linkers.
FIG. 14 shows the pUCWAP5 incorporating a polynucleotide encoding the FIB A.alpha.

1 chain.
FIG. 15 shows the pUCWAP5 incorporating a polynucleotide encoding the FIB B.beta. 1
chain.
FIG. 16 shows the pUCWAP5 plasmid incorporating a polynucleotide encoding the FIB
.gamma. 1 chain.
DETAILED DESCRIPTION OF THE INVENTION
Notwithstanding past failures to express heterologous proteins, such as recombinant
protein C with suitably high activity in several different expression systems, including
transformed mammary cells, it has been discovered that recombinant protein C
characterized by a high percentage of active protein can be obtained in the milk of
transgenic animals that incorporate DNAs according to the present invention. Transgenic
animals of the present invention are produced by introducing into developing embryos
DNA that encodes protein C, such that the DNA is stably incorporated in the DNA of
germ line cells of the mature animal and inherited in normal, mendelian fashion. In
accordance with the invention, DNAs can be introduced into embryos by a variety of
means to produce transgenic animals. For instance, totipotent or pluripotent stem cells
can be transformed by microinjection, calcium phosphate mediated precipitation,
liposome fusion, retroviral infection or by other means. The transformed cells can then be
introduced into embryos and incorporated therein to form transgenic animals. In a
preferred method, developing embryos can be infected with retroviral vectors and
transgenic animals can be formed from the infected embryos. In the most preferred
method, however, the DNAs of the invention are injected into embryos, preferably at the
single-cell stage, which are allowed to develop into mature transgenic animals.
Suitable protein C-encoding DNA used for producing transgenic animals in this fashion
can be obtained using human liver tissue as a source for cloning the hPC gene. The DNA
coding for protein C can be fused, in proper reading frame, with appropriate regulatory
signals, as described in greater detail below, to produce a genetic construct which is then
amplified, for example, by propagation in a bacterial vector, according to conventional
practice.
The amplified construct is thereafter excised from the vector and purified for use in
microinjection. The purification is preferably accomplished by means of high
performance liquid chromatography (HPLC), which rids the construct of contamination
from the bacterial vector and from polysaccharides typically present when other
techniques, such as conventional agarose electroelution, are used. The preferred HPLC
method entails sorbing the construct onto an anion-exchange HPLC support and
selectively eluting the construct from the support, preferably with an aqueous sodium
chloride solution, thereby to eliminate contamination from the vector. (Elution may be
effected by other means, such as a pH gradient.) Alternatively but less preferably, the
excised construct can be purified by ultracentrifugation through an aqueous sucrose
gradient.

Since it is preferable that the construct have the minimum amount of impurities, more
than one cycle of HPLC or other purification is advantageous. In particular, the use of
HPLC-purified DNA for microinjection, as described above, allows for remarkably high
transformation frequencies, on the order of 20% or more in both mice and pigs. All
lactating animals, that is, all mammals, are suitable for use according to the present
invention. Preferred mammals include mice, rats, rabbits, pigs, sheep, goats and cows.
More particularly, mice, pigs, sheep, goats and cows are preferred. Most preferred at
present are mice, pigs and sheep.
DNA constructs useful in the present invention provide a DNA sequence encoding
protein C operably linked to all the cis-acting signals necessary for mammary tissue
specific expression of protein C, post-translational modification of protein C, secretion of
protein C into milk, and full biological activity of protein C.
DNAs useful in the invention include genomic or complementary DNAs that encode
naturally occurring protein C. In a preferred embodiment DNAs encoding human protein
C are employed, including cDNA and genomic DNAs. DNAs encoding protein C from
other species may also be used, such as the protein C encoded by rats, pigs, sheep, cows
and chimpanzees.
In a particularly preferred embodiment, human genomic DNAs encoding protein C are
employed. Among the most highly preferred human genomic DNAs is the fragment of
the human protein C gene beginning 21 basepairs upstream of the protein C start codon
and ending at the NheI site in the 3' end of the protein C gene. This fragment,
approximately 9.4 kb long, contains regulatory elements that engender high expression of
human protein C in the milk of non-human transgenic mammals. Some of these
regulatory elements are the AUG start codon, donor and acceptor splice signals, the
secretion peptide, and the translation termination, transcription termination and
polyadenylation signals.
It will be appreciated that there may be additional regulatory elements in the fragment
that aid the production of transgenic non-human mammals that express high levels of
protein C in their milk. Some of these signals may be transcription or translation control
signals, or those associated with transport out of the cell. Other signals may play a role in
efficient chromosomal integration or stability of the integrated DNA. Various regions of
the fragment may contain such signals, such as the region between the end of exon VIII
and the NheI site in the 3' end of the protein C gene.
It will be readily appreciated that deletional and other mutational techniques may be
employed to elucidate further all the signals in this fragment that confer high levels of
protein C expression in the milk of transgenic animals.
It will also be appreciated that the 9.4 kb protein C fragment described above can be
modified using recombinant DNA techniques in many ways. 3' or 5' portions of the
protein C gene can be added, or a few bases at either end may be removed. Introns can be

removed or added. Portions of one or more introns can be deleted. Additional DNA can
be inserted into them. The sequences of the introns can be altered. Exons can be modified
in accordance with the discussion of modified protein C molecules set forth below. Most
such modified forms of the preferred genomic protein C fragment will not be
significantly changed in their ability in transgenic animals to engender the production of
milk-born protein C. Thus, these substantially similar fragments will be equivalent in the
invention to the particularly disclosed 9.4 kb fragment of human protein C that begins 21
basepairs upstream of the protein C start codon and ends at the NheI site in the 3' end of
the protein C gene.
Modified protein C sequences also can be employed in the present invention. Useful
modifications in this context include but are not limited to those that alter the posttranslational processing of protein C, that alter the size of protein C, that fuse protein C or
portions thereof to portions of another protein, or that alter the active site of protein C.
Preferred modifications include those that provide an activated protein C and those that
provide for activation of protein C in the absence of thrombomodulin. In a preferred
embodiment, modified forms of human protein C are employed.
Such modifications can be introduced into protein C by techniques well known to the art,
such as the synthesis of modified genes by ligation of overlapping oligonucleotide, and
by introducing mutations directly into cloned genes, as by oligonucleotide mediated
mutagenesis, inter alia. The cis-acting regulatory regions useful in the invention include
the promoter used to drive expression of the protein C gene. Promoters useful in the
invention are active in mammary tissue. Particularly useful are promoters that are
specifically active in mammary tissue, i.e., are more active in mammary tissue than in
other tissues under physiological conditions where milk is synthesized. Most preferred
are promoters that are both specific to and efficient in mammary tissue. By "efficient" it
is meant that the promoters are strong promoters in mammary tissue that can support the
synthesis of large amounts of protein for secretion into milk.
Among such promoters, the casein, lactalbumin and lactoglobulin promoters are
preferred, including, but not limited to the .alpha.-, .beta.- and .gamma.-casein promoters
and the .alpha.-lactalbumin and .beta.-lactoglobulin promoters. Preferred among the
promoters are those from rodent (murine and rat), pigs and sheep, especially the rat
.beta.-casein promoter and the sheep .beta.-lactoglobulin promoter. The most preferred
promoters are those that regulate a whey acidic protein (WAP) gene, and the most
preferred WAP promoter is the murine WAP promoter.
A most highly preferred promoter is a mouse whey acidic protein promoter having a
length of greater than about 2.4 kb extending upstream from the unique KpnI site in the
mouse whey acidic protein gene. A mouse whey acidic protein promoter with a length of
approximately 2.4 kb is known as the short WAP promoter. The present invention refers
to the short WAP promoter in various locations and in the figures of the present invention
as having a length of approximately 2.4-2.6 kb as identified by gel electrophoresis. As is
known by persons skilled in the art, this technique provides an approximation of fragment
sizes. The size of 2.4-2.6 kb was determined in 1982 and based on methods of gel

electrophoresis available at that time. The methods were crude and a band of 2.5 kb, for
example, could mean that the fragment is somewhere between 2.3-2.7 kb in size. This
short WAP promoter is composed of the EcoRI-KpnI fragment of the mouse whey acid
protein promoter. It is now known as a result of nucleotide sequencing by techniques well
known to persons skilled in the art that the short WAP promoter is 2410 basepairs in
length, and thus the approximate length of 2.4 kb is the correct size designation. This
short WAP sequence has been deposited with GenBank and has the Accession No.
U38816. Thus, the present invention is intended to encompass a WAP promoter having
more than 2410 basepairs. Additionally, the short WAP promoter is described in Gordon
et al., Bio/Technology 5, 1183-1187 (1987), as having a length of 2.6 kb. This
publication is incorporated in its entirety by reference. Thus, the present invention also
encompasses a WAP promoter having a length greater than 2.6 kb, as determined by the
methods of Gordon et al.
It is the object of the present invention to encompass a mouse whey acidic protein
promoter having a length of greater than the short WAP promoter of 2.4 kb in length with
this long WAP promoter being responsible for the expression of a heterologous
polypeptide at similar or higher levels to that of the Sau3A-KpnI promoter. The promoter
expression levels are measureable by persons skilled in the art given the guidance
provided in the present application.
A most highly preferred promoter is the 4.2 kb Sau3A-Kpn1 promoter fragment of the
mouse whey acidic protein promoter. This promoter fragment is described in detail and
the sequence is provided in Paleyanda et al., Transgenic Research 3: 335-343 (1994),
incorporated herein to disclose inherent properties of the Sau3A-KpnI promoter. The
Paleyanda et al. publication refers to this promoter fragment as having a length of 4.1 kb.
Again as discussed above, the length as determined by gel electrophoresis is approximate.
It is now known as a result of nucleotide sequencing by techniques well known to
persons skilled in the art that this Sau3A-KpnI WAP promoter is 4122 basepairs in
length, and thus the approximate length of 4.1 to 4.2 kb is the correct size designation.
This long WAP sequence was deposited on May 24, 1994 with GenBank and has the
Accession No. X79437.
The Sau3A-KpnI fragment is also contained within the NotI-KpnI fragment as shown in
FIG. 6. This NotI-KpnI fragment containing the Sau3A-KpnI fragment is used to prepare
expression constructs for microinjection for the preparation of transgenic mammals. The
Sau3A-KpnI fragment is modified at the Sau3A end by the addition of a NotI site to
facilitate the preparation of expression vectors. In various locations in the present
application, the plasmid pUCWAP6 contains a long WAP promoter with an approximate
length of 4.1 kb bounded by NotI and KpnI restrictions sites. The NotI site is part of the
plasmid. The NotI-KpnI promoter fragment is 4136 basepairs in length. The present
invention is intended to encompass long WAP promoters with these approximate lengths.
It has been found that this fragment is highly efficacious in directing the production of
high levels of a protein in the milk of a transgenic animal. In the case of human protein C
this mouse whey acidic protein promoter fragment has engendered the production of

active protein C in the milk of transgenic animals in concentrations above 4 mg/ml (by
polyclonal ELISA).
It also has been found that this long WAP promoter fragment is highly efficacious in
directing the production of high levels of polypeptides, particularly blood proteins, such
as Factor IX, Factor VIII, human fibrinogen, thrombin, and von Willebrand's factor in the
milk of a transgenic animal. In the case of Factor IX, transgenic founder animals have
expressed cDNA encoding Factor IX at levels as high as 1500 .mu.g/ml. In the case of
human fibrinogen, this mouse whey acidic protein promoter fragment has engendered the
production of active fibrinogen in the milk of transgenic animals in concentrations of
about 700 .mu.g/ml. See Butler et al., Thrombosis and Haemostasis, 78 (1), 537-542
(1997), herein incorporated in its entirety by reference.
It will be readily appreciated, as for the 9.4 kb protein C genomic DNA discussed above,
the 4.2 kb Sau3A-Kpn1 whey acidic protein promoter fragment can be modified by
recombinant DNA techniques readily available to those of ordinary skill in the art. Thus,
the fragment can be shortened, keeping in mind that the 2.4 kb 5' WAP promoter
fragment gives rise to very much lower yields. It can be lengthened to include more of
the whey acid protein promoter region or other portions of the whey acid protein gene.
Portions can be removed, and DNA can be inserted into the fragment. Internal bases can
be altered. In the majority of cases these alternatives will not affect the ability of this
promoter fragment to induce very high levels of expression. Fragments modified in this
way, giving the expected high yields of protein in transgenic milk, are substantially
similar variants of the 4.2 kb 5' promoter fragment. They also are useful in the present
invention and are functionally equivalent in this respect to the 4.2 kb Sau3A-Kpn1 whey
acidic protein promoter fragment itself.
Also important to the invention are the signal sequences that direct secretion of protein
into the milk of the transgenic animal. In this regard, both endogenous and heterologous
signal sequences are useful in the invention. Generally, the signal peptides of proteins
normally secreted into milk are useful in the invention. The signal sequences of proteins
that occur in high concentration in milk are particularly preferred, such as the signal
peptides of the caseins, lactalbumins and lactoglobulins, including, but not limited to the
signal peptides of the .alpha.-, .beta.- and .gamma.-caseins and .alpha.-lactalbumin and
.beta.-lactoglobulin. More particularly, the signal sequence of whey acidic protein is
preferred, most particularly the signal sequence of the murine whey acidic protein.
Also particularly preferred are the signal peptides of secreted coagulation factors.
Especially preferred in this regard are the signal peptides of protein C, and t-PA. Most
especially preferred is the secretion signal of human protein C.
Among the sequences that regulate transcription that are useful in the invention, in
addition to the promoter sequences discussed above, are enhancers, splice signals,
transcription termination signals and polyadenylation sites, among others. Particularly
useful regulatory sequences increase the efficiency of mammary cell specific expression
of protein C in transgenic animals. Especially useful in this regard are the other

transcription regulatory sequences of genes expressed at high levels in mammary cells,
such as the .alpha.-, .beta.-and .gamma.-casein genes and the .alpha.-lactalbumin and
.beta.-lactoglobulin genes mentioned above. Preferred sources for regulatory sequences in
this regard are rodents (mice and rats), pigs and sheep. Exemplary of preferred regulatory
sequences are those associated with the rat .beta.-casein gene and the sheep .beta.lactoglobulin gene, respectively. The regulatory sequences most preferred for use in the
present invention are those associated with whey acidic protein genes. Particularly
preferred in this context are regulatory sequences of the murine whey acidic protein.
Among the sequences that regulate translation, in addition to the signal sequences
discussed above, are ribosome binding sites and sequences that augment the stability the
protein C mRNA. Especially useful are the translation regulatory sequences of genes
expressed at high levels in mammary cells. For instance, the regulatory sequences of the
.alpha.-, .beta.- and .gamma.-casein genes and the .alpha.-lactalbumin and .beta.lactoglobulin genes are preferred, especially those from rodents (mice and rats), pigs and
sheep. Even more particularly preferred are the regulatory sequences of rat .beta.-casein
and the sheep .beta.-lactoglobulin genes. The most preferred translational regulatory
sequences of the invention are those of the whey acidic protein and the protein C genes.
And the most particularly preferred regulatory sequences are those of the murine whey
acidic protein and human protein C, including human genomic protein C and human
protein C cDNA constructs, and including human protein C cDNA constructs that contain
intron sequences. Among these, the most highly preferred are the regulatory sequences of
the human protein C gene in the region beginning 21 basepairs upstream of the protein C
start codon and ending at the NheI site in the 3' end of the protein C gene, and the
regulatory sequences of the mouse whey acidic protein promoter in the 5' 4.2 kb Sau3AKpn1 promoter fragment of the mouse whey acidic protein promoter, most particularly
when they are used together.
Especially useful in the present invention are sequences that advantageously modulate
post-translational modifications of protein C, such that the protein C produced in the
transgenic animals of the invention is active. In particular, the genomic sequences of the
human protein C gene are preferred. Thus, in accordance with the present invention a
DNA sequence that encodes protein C is operably linked to cis-acting regulatory
sequences which allow for efficient expression of protein C in milk. The resulting
chimeric DNA is introduced into a mammalian embryo, where it integrates into the
embryonic genome and becomes part of the heritable genetic endowment of all the cells,
including the germ line cells, of the adult which develops from the embryo. The protein C
which is expressed in the mammary tissue and secreted into the milk of a transgenic
mammal obtained in this manner displays a surprisingly high percentage of active
protein, as measured by enzymatic and coagulation-inhibition assays which are
conventionally employed to detect protein C activity, such as ELISAs, chromogenic
activity assays and coagulation inhibition assays. Levels of active protein on the order of
80% to 90% or more are characteristic of the protein C expressed in accordance with the
present invention. Obtaining milk from a transgenic animal within the present invention
is accomplished by conventional means. McBurney et al., J. Lab. Clin. Med. 64: 485
(1964). The protein C contained in such milk can be purified by known means without

unduly affecting activity. One suitable approach to purification in this regard is
immunoaffinity chromatography. Alternatively, the expressed protein C can be isolated
from the milk by other conventional means, for instance, by the method of Kisiel, J. Clin.
Invest. 64: 761 (1979). In any event, it is preferred that protein C produced in milk
pursuant to the present invention should be isolated as soon as possible after the milk is
obtained from the transgenic mammal, thereby to mitigate any deleterious effect(s) on the
stability of the protein.
The present invention is further described by reference to the following, illustrative
examples.
EXAMPLE 1
DNAs Useful for Expressing Protein C in Transgenic Animals
The entire murine WAP gene including 2.5 kb of 5' untranslated sequence and 3'
untranslated regions was cloned by standard methods. See Campbell et al., Nucleic Acids
Res. 12: 8685 (1984). The human placental cDNA for human protein C was obtained
from C. Shoemacker. Human genomic DNAs encoding protein C were cloned by
standard methods from a human placental genomic library. The 9.4 kb fragment was
assembled from two genomic clones and a SalI, MseI ended 60 bp synthetic
oligonucleotide that was added to the 5' end of the gene.
Standard recombinant DNA techniques were employed to generate the vectors and
expression constructs of the preferred embodiments, and for other manipulations of
DNA, as set forth below. See Sambrook et al., MOLECULAR CLONING, A
LABORATORY MANUAL, Vol. 1-3 (Cold Spring Harbor Press 1989).
(1) WAPpC1
A DNA construct called WAPpC1 was made, consisting of the entire murine WAP gene
containing one copy of human protein C cDNA inserted at the unique KpnI site, 24 base
pairs 3' of the transcriptional start site of the WAP gene (FIG. 1). This WAP-protein C
construct was ligated into a bluescribe vector (Stratagene) to facilitate further
manipulation.
(2) WAPpC2
WAPpC2 is similar to WAPpC1, comprising the entire murine WAP gene and human
protein C cDNA but differs from WAPpC1 in lacking artefactual 5' flanking sequences
present in WAPpC1 as a result of cloning procedures used to make that construct.
Specifically, 33 bp 5' to the protein C ATG and 118 "A's" at the 3' end of the protein C
cDNA were removed by PCR, and new KpnI sites were added at the 5' and 3' ends.
EXAMPLE 2

Preparation of DNAs for Microinjection
DNA for microinjection was prepared according to the procedures described below for
DNA from WAPpC1.
The 9 kb WAPpC1 fragment was removed from the vector with the restriction enzyme
EcoRI. After digestion with EcoRI the solution containing the WAPpC1 DNA was
brought to 10 mM magnesium, 20 mM EDTA and 0.1% SDS and then extracted with
phenol/chloroform. DNA was precipitated from the aqueous layer with 2.5 volumes of
ethanol in the presence of 0.3 M sodium acetate at -20.degree. C. overnight. After
centrifugation, the pellet was washed with 70% ethanol, dried, and resuspended in sterile
distilled water.
DNA for microinjection was purified by HPLC. The digested DNA was precipitated with
isopropanol and then dissolved in TE buffer at 0.3 .mu.g/ml. Fragments were purified by
HPLC using a Waters GEN FAX PAC HPLC column. The column was run isocratically
using a buffer consisting of 25 mM Tris-HCl (pH 7.5), 1 mM sodium EDTA, and 0.63 M
NaCl. This is the minimum NaCl concentration that will elute the large construct
fragment and results in the best resolution from the smaller vector fragment which elutes
just prior to the construct fragment. About 15 .mu.g of digested DNA was loaded on the
column at a time. The construct-fragment samples from all of the chromatographic runs
were then pooled, reprecipitated, and run through the column a second time. Results
reported below, for both pigs and mice, were generated using HPLC-purified DNA.
DNA concentrations were determined by agarose gel electrophoresis by staining with
ethidium bromide and comparing the fluorescent intensity of an aliquot of the DNA with
the intensity of standards. Samples were then adjusted to 10 .mu.g/ml and stored at 20.degree. C., prior to microinjection.
EXAMPLE 3
Transgenic Animals
(1) Mice
Transgenic mice were produced essentially as described by Hogan et al.,
MANIPULATING THE MOUSE EMBRYO (Cold Spring Harbor Press 1986). The
procedures employed are outlined below.
Glass needles for micro-injection were prepared using a micropipet puller and
microforge. Injections were performed using a Nikon microscope having Hoffman
Modulation Contrast optics, with Narashigi micromanipulators and a pico-injector driven
by N.sub.2 (Narashigi). Fertilized mouse embryos were surgically removed from the
oviducts of superovulated female CD-1 mice and placed into M2 medium. Cumulus cells
were removed from the embryos with hyaluronidase at 300 .mu.g/ml. The embryos were
then rinsed in new M2 medium, and transferred into M16 medium for storage at

37.degree. C. prior to injection.
After injecting the DNA solution into the male pronucleus, embryos were implanted into
avertin-anesthetized CD-1 recipient females made pseudo-pregnant by mating with
vasectomized males. Embryos were allowed to come to term and the newborn mice were
analyzed for the presence of the transgene as described below.
(2) Pigs
Embryos were recovered from the oviduct. They were placed into a 1.5 ml microfuge
tube containing approximately 0.5 ml embryo transfer media (phosphate buffered saline
+10% fetal calf serum, Gibco BRL). These were then centrifuged for 12 minutes at
16,000.times.g RCF (13,450 RPM) in a microcentrifuge (Allied Instruments, model
235C). Embryos were removed from the microfuge tube with a drawn and polished
Pasteur pipette and placed into a 35 mm petri dish for examination. If the cytoplasm was
still opaque with lipid such that pronuclei are not visible, the embryos were centrifuged
again for 15 minutes. Embryos to be microinjected were placed into a microdrop of
media (approximately 100 .mu.l) in the center of the lid of a 100 mm petri dish. Silicone
oil was used to cover the microdrop and fill the lid to prevent media from evaporating.
The petri dish lid containing the embryos was set onto an inverted microscope (Carl
Zeiss) equipped with both a heated stage and Hoffmnan Modulation Contrast optics
(200.times.final magnification). A finely drawn (Kopf Vertical Pipette Puller, model 720)
and polished (Narishige microforge, model MF-35) micropipette was used to stabilize the
embryos while about 1-2 picoliters of HPLC-purified DNA solution containing
approximately 200-500 copies of DNA construct was delivered into the male pronucleus
with another finely drawn micropipette. Embryos surviving the microinjection process as
judged by morphological observation were loaded into a polypropylene tube (2 mm ID)
for transfer into the recipient pig.
(3) Other Animals
Methods for microinjection of other animal species are similar to the methods set forth
above.
EXAMPLE 4
Assessment via PCR of WAP/hPC Constructs in Transgenic Animals
(1) Preparation of DNA Form Transgenic Animals
DNA can be prepared from tissue of a transgenic animal of any species by the method
exemplified below for mice.
A 5 mm piece of mouse tail was removed from young, potentially transgenic mice at
weaning (3 weeks of age), minced, and treated with proteinase K and SDS at 37.degree.
C. overnight. The mixture was then incubated with DNase-free RNase at 37.degree. C.

for 1-2 hours. DNA was precipitated from the mixture with sodium acetate and ethanol at
-20.degree. C. overnight, collected by centrifugation, washed in 70% ethanol and dried.
The dried DNA pellet was used directly for PCR. In some cases the mixture was
extracted extensively with phenol/chloroform prior to ethanol precipitation.
Essentially the same technique was used to prepare DNA from pigs, and the same or
similar techniques can be used to prepare DNA from other animals.
(2) Oligonucleotide Probes Used in the PCR Assay
Oligonucleotide pairs were used to prime polymerase chain reactions that detected the
presence of WAP-protein C constructs in the transgenic animals. These pairs and their
extension products are shown schematically in FIG. 2. Oligonucleotide pairs that bridge
the region from the WAP sequences 5' of the KpnI site and the endogenous WAP
sequences which naturally lie 3' of the KpnI site also provided positive controls in mice.
(3) PCR Reaction Conditions and Product Analysis
PCR reactions were performed using an annealing temperature of 58.degree. C., a
denaturation temperature of 94.degree. C., and an extension temperature of 72.degree. C.,
using 100 ng of oligo primers and 50 ng of (genomic) template DNA per reaction, and
cycling through the temperatures 40 times using an automatic temperature cycler (M.J.
Research).
PCR reactions were analyzed by running 20% of the reaction products on agarose gels
and identifying fragment sizes by comparison with marker DNA fragments.
(4) Results of PCR Analysis of Transgenic Animals
PCR analysis of potentially transgenic mice and pigs which developed from embryos
microinjected with WAPpC1 and WAPpC2 constructs are summarized in Table 2. The
results show that WAPpC constructs frequently integrated into the embryonic genomes of
both mice and pigs. Furthermore, mendelian transmission was observed in 5 of the 16
mice which were tested.
TABLE 2
Whey Acid Protein-Protein C Construct Integration Rates
Animal
# Tested
# Positive
Integration Rate
Mice
105
30
29%
Pigs
23
5
22%
Mendelian Transmission in Transgenic Mice 5/16 Tested = 31%

EXAMPLE 5
Preparation of Milk and Whey from Transgenic Animals
Lactating mice were milked an average of 3 times per week. The mice were first

separated from their young for approximately 5 hours. They were then anesthetized with
0.4 ml avertin at 2.5% (I.M.), and 0.2 ml oxytocin was then administered at 2.5 IU/ml
(I.P.) to permit release of the milk. A milking device consisting of a vacuum pump (2.5
psi) and syringe with an eppendorf tip was used to direct milk into an eppendorf tube.
During collection, milk was placed on ice until all samples were obtained.
To prepare whey, milk was diluted 1:1 with TS buffer (0.03 M Tris pH 7.4; 0.06 NaCl)
and centrifuged in a TLA-100 rotor in a Beckman TL-100 table top ultracentrifuge at
51,000 rpm (89,000.times.g) for 30 minutes at 4.degree. C. After centrifugation the tubes
were put on ice, and the whey was collected with an 18 gauge needle, leaving the casein
pellet and upper cream layer in the tube. To remove solids or cream that co-transferred
during the initial recovery, the whey obtained from the first centrifugation was subjected
to a second spin at 12,000 rpm for 30 minutes at 4.degree. C. in a TMA-4 rotor in a Tomy
MTX-150 centrifuge. Following the second spin the tubes were place on ice and the
whey was recovered as before.
EXAMPLE 6
Determination by ELISA of Protein C Produced by Transgenic Mammals
An ELISA was used to measure the amount of protein C protein produced by transgenic
animals in their milk or whey. Two monoclonal antibodies, 7D7B10 and 12A8, and a
polyclonal antiserum were used in the ELISAs, and a variety of other protein C specific
antibodies could be employed. The 7D7B10 monoclonal is specific for the NH.sub.2
terminus of the light chain of protein C. 12A8 is specific for the reactive site on the heavy
chain of protein C. Microtiter plate wells were coated overnight at 4.degree. C. with 3
.mu.g/ml of monoclonal antibody in 50 .mu.l of 0.1 M sodium bicarbonate buffer, pH 8.3.
The wells were washed once with TET buffer (0.01 M Tris pH 7.5; 0.01 M EDTA;
0.02% tween-20, pH 7.45) and then blocked with 1% BSA in PBS using 400 .mu.l per
well for 1 hour at 37.degree. C. Plates were again washed with TET buffer (5.times.)
followed by addition of 100 .mu.l of sample whey or normal whey spiked with human
protein C from plasma, to generate a standard curve. After washing 5.times. with TET
buffer, horse radish peroxidase (HRP)-conjugated to rabbit anti-hPC was diluted 1:1000
in 0.1% BSA/TET and 100 .mu.l was added per well and incubated for 2 hours at room
temperature, with shaking at 100 rpm. After again washing 5 times with TET buffer, 100
.mu.l of orthophenyldiamine (OPD), from a stock solution made by dissolving one tablet
of OPD in 20 ml of 0.1 M citrate-phosphate buffer (pH 5.0), were added to each well.
After 10 minutes at room temperature the reaction was stopped with 1 N sulfuric acid.
The extent of the reaction was determined by measuring product absorption at 490 nm.
The result of an ELISA analysis of the milk from one transgenic mouse (Mouse No. 5) is
shown in FIG. 3. Standard curves were obtained for a monoclonal antibody, 12AB, and a
rabbit polyclonal antibody, tittered against human protein C which was obtained by
immunoaffinity chromatography over immobilized 7D7B10 antibody. The milk sample,
taken from transgenic Mouse No. 5, contained approximately 200 ng/ml protein C.

To assure proper protein C structure as judged by immunocapture by two different
monoclonal antibodies, as well as by a polyclonal mixture of antibodies, the samples for
several different transgenic mice were screened by ELISAs. Table 2A shows essentially
equivalent antigen levels, as judged by three different immunocaptures and detection by
ELISA. The majority of mice produced by microinjection of WAPpC1 produced antigen
levels in the 1-to-4-.mu.g/ml range.

MOUSE
ID-DAY
Y52-15
Y57-15

TABLE 2A
hPC ANTIGEN ELISA (NG/ML)
MONOCLONAL
MONOCLONAL
LC-CAPTURE
HC-CAPTURE
1820
3530
930
1150

POLYCLONAL
CAPTURE
4100
2880

The concentration of human protein C in whey obtained from transgenic mice, as well as
milk, was also determined in this manner, with equivalent results.
Similar assays were routinely carried out to assay protein C in milk obtained from
transgenic animals. Results obtained using the 7D7B10 antibody in light-chain capture
ELISAs are compiled in Table 3, which summarizes the concentration of protein C in
milk obtained from transgenic mice during the first four lactation periods. Dashes
indicate that no test was done. All of the animals provided significant levels of protein C
in their milk. Preliminary results also indicate that the second lactation period is
sometimes superior to the other periods tested.
TABLE 3
hPC ELISA SCREENING (LIGHT CHAIN CAPTURE)
PC-Ag (.mu.g/ml)
Day of Lactation
MOUSE ID
5-6
8-9
11-12
Y68-L2
-1.05
-Y51-L2
-1.08
-Y51-L3
-2.80
1.30
Y52-L1
-0.55
0.65
Y52-L2
-1.52
-Y57-L1
--0.52
Y57-L2
1.47
-0.98
R03-L2
1.90
2.88
3.01
R12-L1
-0.60
-R12-L2
-2.98
2.48

13-15
-0.56
1.79
-0.95
1.35
---2.40

Human protein C in the milk obtained from other species can be measured by the same
methods. Thus, protein C from human plasma spiked into pig milk was accurately
detected via the above-described ELISA.
EXAMPLE 7
Assay for Protein C Amidolytic Activity Using the Chromogenic Substrate S-2366

(1) Microtiter Well Assay
The enzymatic activity of protein C in the milk of transgenic animals was measured
directly using a chromogenic assay essentially as described by Odegaard et al.,
Haemostasis 17: 109 (1989). In this assay microtiter plate wells were coated with the
7D7B10 monoclonal antibody (50 .mu.g/ml) in 50 .mu.l of 0.1 M bicarbonate buffer, pH
8.6 at 4.degree. C. overnight. Plates were then rinsed with TET buffer (0.1 M Tris; 0.03
M EDTA; 0.05% tween-20) and blocked with 400 .mu.l/well 1% BSA in PBS and
incubated at room temperature for 1 to 1.5 hours. After rinsing 3 times with TET buffer,
50 .mu.l of whey sample and 50 .mu.l of 0.1 M Tris pH 7.5, 0.03 M EDTA was added per
well and incubated at room temperature for 2 hours. Plates were washed 3 times in TET
buffer. The captured human protein C was activated by adding 120 .mu.l of Protac.TM., a
commercial reagent containing a snake-venom enzyme (12 ml distilled water per vial), 30
.mu.l TSP buffer and 0.1% BSA, pH 7.5, per well. After incubation for 6-10 minutes at
room temperature, 120 .mu.l S-2366 (Kabi substrate) at 25 mg/10.8 ml Tris pH 7.8 was
added to each well and the plates were incubated for 2-8 hours at room temperature, or
several days at 4.degree. C. The amount of protein C activity in each sample was
determined by measuring formation of the reaction product by absorption at 405 mm.
Results obtained using milk and whey from a transgenic mouse and the pooled milk and
whey of several transgenic mice appear in Table 4, which shows the amount and the
specific activity of protein C in the samples. Note that the samples were obtained either
during the first lactation period, L1, or were obtained from a second and third lactation,
L2 and L3. The specific activity of the human protein C obtained from transgenic mice
determined in these assays, 205 units (U) per mg, is similar to that of human protein C of
similar purity obtained from natural sources. (A "unit" is defmed by pooling blood from
many individuals and determining activity in 1 ml of the pooled blood.)
TABLE 4
Protac .TM. -Specific Amidolytic Activity Upon S-2366
U/ml
.mu.g Ag/ml
U/mg
Reconstituted Whey
0.07
0.34
206
Y52-L1 Pool*
Y52-L1 Milk Pool*
0.23
1.12
Transgenic Whey Pool**
1.12
0.55
205
Transgenic Milk Pool**
0.43
2.10
*Pooled milk from day 5-15.
**L2 and L3 from mice Y51, Y52, Y57, R03, R12.

(2) Amidolytic Activity Assay on Nitrocellulose
Whey proteins were resolved by electrophoresis through polyacrylamide gels under nonreducing conditions in the presence of SDS. Following electrophoresis proteins were
transferred out of the gel and immobilized on a nitrocellulose membrane by
electroblotting. SDS was removed from the membrane by thorough washing in 0.05 M
Tris-Cl, 0.175 M NaCl, 0.25% Triton X-100, pH 8.0, and the membrane was then

equilibrated in 0.25 M Tris-Cl pH 8.0. Following equilibration the membrane was
incubated in Protac C, 0.25 U/ml in distilled water. A 1% agarose indicator gel in 25 mM
Tris-Cl pH 8 containing 1 mM chromogenic substrate S-2366 was then placed onto the
gel, and the filter and gel overlay were incubated under moist conditions for 30-90
minutes at 37.degree. C. Colored bands generated by protein C activity on the filter were
visualized under U.V. light, and photographed.
FIG. 8 shows the results obtained by this assay for milk produced by transgenic mice that
were stably transformed with a double stranded DNA comprising the 5' 4.2 kb WAP
promoter ligated via a linker to the 9.4 kb human genomic protein C fragment. All of
these transgenic mice produced amidolytically active protein C in their milk, giving rise
in the blots to a strong band and a weak band of amidolytic activity (FIG. 8, panel A).
Notably, bands of the same migration were detected in each whey sample when a similar
blot was probed with an anti-protein C antibody (FIG. 8, panel B).
EXAMPLE 8
Determination of Protein C Produced in Transgenic Mammals by Activated Partial
Thromboplastin Clotting Time Assay
The activity of protein C was also measured in a clotting time assay, the activated partial
thromboplastin clotting time assay (APTT). In this assay, each well of a plastic Coag-amate tray received 90 .mu.l of PC-deficient plasma plus 10 .mu.l of an APC standard or
unknown, diluted with Tris/saline/BSA. The tray was then placed on an automated
analyzer (APTT mode, 240 second activation). The run was started, which automatically
performed the addition of 100 .mu.l of APTT reagent and 100 .mu.l of 0.025 M
CaCl.sub.2. Data obtained using a standard APC preparation was fitted to the equation yax+b where y=clotting time and x=APC, which was then used to determine the amount of
APC in a sample.
The result of an APTT assay of whey pooled from transgenic mice is shown in FIG. 4.
The standard curves in the figure correlate the activity determined by the APTT assay
with the amount of active human protein C in mouse milk or mouse whey. The activity in
the APTT assay of the whey sample obtained from the transgenic mouse corresponded to
a concentration of approximately 0.57 .mu.g/ml, interpolated from the standard curve for
human protein C in whey. An ELISA (not shown) of the same whey sample detected
approximately 0.60 .mu.g/ml of human protein C, as protein. Thus, within the normal
range of error of these assays, human protein C produced in transgenic mice is as active
as the control human protein C.
EXAMPLE 9
Mapping of Calcium Dependent Conformer by Metal-Dependent Immunoaffinity
Standard ELISAs were run in normal mouse milk whey with varying concentrations of
hPC or hPC without Gla regions in the presence of 25 mM EDTA. After capture by

7D7B10, an assay replicating that effected with 25 mM EDTA was treated with several
washes of 25 mM CaCl.sub.2, and then was followed by the ELISA detection protocol
described previously. While de-Gla protein remained bound to the capture antibody in the
presence of CaCl.sub.2, the PC standard did not remain bound in the presence of added
CaCl.sub.2. It was observed that whey from the transgenic mouse Y57 behaved in a
similar manner to the .gamma.-carboxylated native PC, suggesting that it is also
.gamma.-carboxylated like the native molecule.
EXAMPLE 10
Purification of Human Protein C from the Milk of Transgenic Animals
(1) Preparation of Whey Samples
Milk from several WAPpC1 transgenic mouse lines was pooled, chilled on ice, diluted 6fold with 50 mM Tris-HCl, 0.15 M NaCl pH 7.2 (TBS) (1 ml milk per 5 ml TBS), and
centrifuged at 125,000.times.g for 30 minutes at 4.degree. C. Following centrifugation,
the whey was collected and pooled using a pasteur pipet and pooled, being careful not to
disturb the fatty overlayer or the casein pellet. Samples were removed from the pool for
later assay and then both the samples and the pooled whey were frozen and stored at 90.degree. C. Human protein C in samples was determined by ELISA, as described
above.
Individual whey pools were thawed at 2.degree. C.C, combined, and the amount of
human protein C (hPC) in the combined pool was determined by ELISA using the
7D7B10 monoclonal antibody (Mab). The combined pool contained approximately 30
.mu.g hPC, determined by this assay, which was within 20% of the total determined by
adding determinations of the individual pools.
The combined pool, approximately 150 ml, was dialyzed (14,000 MW cutoff) against 25
mM EDTA-TBS diluted 5-fold with pure water. The dialyzed whey was concentrated 5fold by lyophilization and subsequent reconstitution with nanopure water, to yield a final
buffer concentration equivalent to 25 mM EDTA in TBS, and a 5-fold increase in protein
concentration. The concentrated whey contained 930 mg protein, as estimated by optical
absorption at 280 nm, at 16 mg/ml.
2) Immunoaffinity Chromatography
The resin immunosorbent (Affiprep.TM.) used to purify human protein C in the whey of
transgenic mice contained 3.3 mg 7D7B10 Mab/ml of Affiprep resin. The 7d7B10
Affiprep resin was assessed by mock immunopurification using 30 .mu.g of plasma
derived hPC doped into control (nontransgenic) mouse whey. Approximately the same
relative amount of total protein was loaded onto the column (660 mg on a 10 mL
Affiprep) and otherwise processed as described below.
Freshly concentrated whey (16 mg/ml, 930 mg total protein, as determined by optical

absorption at 280 nm) was batch-loaded onto 13 ml of 7D7B10 Affiprep containing 3.3
mg 7D7B10 Mab/ml resin for 4 hours at 2.degree. C., without addition of carrier protein.
The column was fresh and the high total (background) protein loading was thought to be
enough to condition the column. The resin was then loaded into a 1 cm diameter column
and washed with 25 mM EDTA-TBS until baseline optical density (O.D.) was detected at
280 nm (3 column volumes to obtain <0.0005 O.D.)
The column was then eluted with 25 mM CaCl.sub.2 in TBS pH 7.2, followed by 100
mM CaCl.sub.2 in TBS, followed by 4 M NaCl, followed by 2 M Na thiocyanate at 0.5
ml/min. The column was re-equilibrated with 5 column volumes of 25 mM EDTA-TBS,
0.02% sodium azide.
All peak pools were dialyzed in a 100-fold dilution (by nanopure water) of 50 mM
imidazole, 0.1 M NaCl buffer using a 14,000 MW cutoff dialysis tubing, then
lyophilized, then reconstituted to 50 mM imidazole, 0.1 NaCl buffer strength using
nanopure water resulting in a 100-fold concentration of protein.
Samples of these eluate pool concentrates were prepared as per the method of Laemmli
(1970), applied to a 15 well, 9 cm.times.2 cm, 4% stacking gel above a 7.5 cm, 7.5%
resolving (30%: 2.7% bis) sodium dodecylsulphate polyacrylamide gel and
electrophoresed (SDS-PAGE). After electrophoresis, the gel was stained with 1.25%
Coomassie Blue dye solution.
The area of the eluate peaks obtained from immunopurification of whey from WAPpC1transgenic mice was found to be very similar to the mock trial using an equivalent
amount of (plasma derived) hPC-doped whey from control mice. Assay of 100-fold
concentrated 25 mM CaCl.sub.2 eluate product from WAPpC1 transgenics showed 40%
yield based upon densitometry of SDS-PAGE stained with Coomassie Blue (yield not
determined for mock purification). The total peak areas from mock- and WAPpC1-whey
were approximately the same for all eluate peaks including the 2 M Na thiocyanate peak.
Approximately 2 .mu.g of hPC antigen (ELISA with immunocapture using 7D7B10
Mab) was detected in the column fallthrough which had been combined with EDTA-TBS
wash. Approximately 14 .mu.g of hPC was detected in the 25 mM Ca.sup.2+ eluate pool,
less than 0.1 .mu.g hPC antigen in the 100 mM Ca.sup.2+ eluate pool, no hPC antigen
was detected in the 4 M NaCl pool, approximately 10 .mu.g of hPC was detected in the 2
M Na thiocynate eluate pool. Thus, 87% of the hPC antigen applied to the column was
accounted for in the total antigen recovered from column effluents. A 47% antigen yield
was obtained based upon the hPC antigen recovered in the 25 mM Ca.sup.2+ eluate peak.
The starting whey applied to the column, the 2 M sodium thiocyanate eluate, the 25 mM
Ca.sup.2+ eluate product, and a reference hPC derived from plasma by the American Red
Cross (Lot #28300277, supplied by Dr. Carolyn Orthner) were analyzed by SDS-PAGE,
both reduced and non-reduced. The 2 M sodium thiocynate and 25 mM Ca.sup.2+ eluate
pools were concentrated as described above and 4 .mu.g of antigen applied to the gel for
each lane. The immunopurified hPC reference was applied to the gel as 4 .mu.g total
protein based upon O.D. at 280 nm. Scanning densitometry of this reference hPC

indicated that the sample was greater than 99% pure on nonreduced SDS-PAGE, and
71% pure on reduced SDS-PAGE. Subsequent antigen assays performed on the hPC
reference material indicated the concentration of the sample to be such that only 2.7
.mu.g of the reference sample was applied to the gel. The 25 mM Ca.sup.2+ eluate
product is greater than 94% pure based upon non-reduced SDS-PAGE and 86% pure
based upon reduced SDS-PAGE. The staining intensity of the 25 mM Ca.sup.2+ eluate
lanes is consistent with our previous experience for 4 .mu.g antigen applications. The
bands corresponding to reference hPC possessed lighter intensity relative to the 25 mM
Ca.sup.2+ eluate. A slightly split band at approximately 62,000 relative molecular weight
(Mr) is seen for both the non-reduced reference hPC and the 25 mM Ca.sup.2+ eluate. A
doublet at about 40,000 Mr and a diffuse single band at 22,000 Mr is seen for both the
reduced reference hPC and 25 mM Ca.sup.2+ eluate. The 22,000 Mr band appearing in
the hPC reference is seen to be somewhat more diffuse or heterogeneous than the similar
band appearing in the 25 mM Ca.sup.2+ eluate from the whey of transgenic mice. The
sodium thiocyanate peak showed a band in excess of 180,000 Mr in the nonreduced
sample and multiple bands at 50,000 Mr and 25,000 Mr in the reduced sample.
The chromatography of the WAPpC1-whey was nearly identical to the mock run using
plasma-derived hPC doped into control whey. The total areas and yields of hPC in the 25
mM Ca.sup.2+ eluates and areas of 2 M sodium thiocyanate peaks for both runs were
similar and thus the binding characteristics of the 7D7B10 Mab onto transgenic hPC or
plasma-derived hPC were similar. This is consistent with the similarity found between
plasma-derived and transgenic hPC Ca.sup.2+- dependent conformers as judged by
ELISA assays using the 7D7B10 Mab to immunocapture from whey. The primary
structure as judged by SDS-PAGE appears to be similar, with the amount of .alpha.-form
and .beta.-form heavy chain being essentially the same for plasma-derived and transgenic
hPC; the transgenic having 68% .alpha.-form and 32% .beta.-form while the plasmaderived material possessed 69% .alpha.-form and 31% .beta.-form. The light chains were
also similar in size for both reference and transgenic hPC. Previous experience with SDSPAGE using Coomassie Blue staining of hPC has shown linearity for both chains over
the range of 2-5 .mu.g hPC applied to the gel. Thus, much of the elements of posttranslational, proteolytic processing appears to have occurred properly in the mammary
tissue.
The purity of these runs also demonstrates the satisfactory utility of the
immunopurification procedure developed for the murine system. It is believed that the
tight binding of the hPC antigen found by ELISA in the 2 M thiocyanate peak of the
whey from transgenic mice (assay not done for mock run) is typical of yields found for
fresh immunosorbents and not due to an aberrant hPC structure. The total background
protein did not seem to condition the column and thus the interaction is thought to be
specific with the 7D7B 10 Mab. Overall, this two step procedure results in a minimum
purification factor of 27,000 for the hPC recovered from mouse milk. A large-scale
purification process could employ a citrate or EDTA precipitation coupled with low
speed centrifugation in place of the ultracentrifugation step used for mouse milk.
Both amidolytic and anti-coagulant assays were performed upon immunopurified milk

from transgenic mice. Within the sensitivity of these assays, the amidolytic and anticoagulant activity was the same as plasma-derived immunopurified protein C. For both
types of assays, the specific activity was greater than 270 U/mg.
EXAMPLE 11
Highly Efficient Expression of Active Protein C in Transgenic Mammals Using a Long
Mouse Whey Acid Protein Promoter Fragment and a Human Genomic Protein C
Fragment
(A) DNA Constructs
The 5' 4.2 kb Sau3A-Kpn1 promoter fragment of the mouse whey acidic protein
promoter was cloned by standard techniques. This Sau3A-KpnI WAP promoter is 4122
basepairs in length and has the GenBank Accession No. X79437. The nucleotide
sequence of the Sau3A-KpnI WAP promoter (SEQ ID NO: 1) is shown in FIG. 9. The
9.4 kb genomic fragment of human protein C beginning 21 basepairs upstream of the "A"
in the protein C start codon and ending at the NheI site in the 3' end of the protein C gene
also was cloned by standard techniques. The 4.2 kb promoter fragment and the 9.4 kb
protein C fragment were joined using a SalI linker, as shown in FIG. 6.
(B) Production of Transgenic Animals
DNA was prepared and injected into mouse and pig embryos as described hereinabove.
Animals were tested for integration of the DNA by PCR, also as described above. Stable
integration of the construct was detected in both mice and pigs.
(C) Protein C in the Milk of Transgenic Mice
The mice were reared to maturity, crossed and milk was obtained from lactating females.
FIG. 7 depicts SDS-PAGE and western blot analysis of whey from six transgenic mice.
As shown in panel A, transgenic mouse whey (lanes 1-6) and normal mouse whey (lane
7) gave rise to substantially the same silver stain pattern of bands after SDS-PAGE. As
shown panel B, human protein C readily was detected in the transgenic mice whey (lanes
1-6), but not in normal mouse whey (7), when the samples were blotted onto
nitrocellulose, probed with an anti-human protein C antibody, and visualized by
chemiluminescence. The pattern of bands detected by the anti-human protein C antibody
in the transgenic mouse whey was very similar to the pattern of bands detected in purified
human protein C (lane 8).
As shown in FIG. 8, protein C activity readily could be detected in transgenic mouse
whey. Panel B in the figure shows the pattern of human protein C in mouse whey
samples resolved by SDS-PAGE under non-reducing conditions. Protein C was
visualized by blotting onto nitrocellulose, probing the filter with an anti-human protein C
antibody and detecting antibody binding by a secondary-antibody- enzyme conjugate and

the chromogenic substrate 4-chloro-1-naphthol. Protein C reactive bands were
substantially the same in transgenic mice (lanes 3-8) and purified human protein C (lane
1), and were absent from normal mouse whey (lane 2).
Amidolytic activity in the samples is shown in Panel A. An agarose gel overlay
containing chromogenic substrate revealed enzyme activity in whey from each transgenic
mouse (lanes 3-8) and in purified human protein C (lane 1), but not in normal mouse
whey (lane 2). The amounts of human protein C produced by the transgenic mice in their
milk also was determined. Table 5 shows the amounts of human protein C detected in the
milk of six transgenic mice, as determined by 12A8 monoclonal ELISA and by sheep
anti-human protein C polyclonal ELISA. The table also shows protein C amidolytic
activity in whey from the same samples. The ELISAs and the amidolytic activity assay
were performed as described hereinabove.
As shown in the Table 5, protein C concentrations in the transgenic mice by monoclonal
ELISA ranged from approximately 0.05 mg/ml to approximately 1.69 mg/ml. The
concentration of protein C in the milk of these mice was at least 40 fold more than the
concentration of protein C observed in other transgenic mice, such as those noted in
Table 2A, as set forth hereinabove.
Concentrations measured by polyclonal ELISA ranged from 0.14 to 4 mg/ml, exceeding
even more dramatically the concentrations attained with the 2.4 kb 5' WAP promoter, the
highest of which, as set forth in Table 2A, was 0.0041 mg/ml.
In addition, whey samples from the transgenic mice were assayed for amidolytic activity
and the results were compared with amidolytic activity of protein C in plasma.
Amidolytic activity in the samples is shown in Table 5, expressed as the per cent of
protein C activity in plasma. The concentration of protein C in the whey samples was
adjusted to equal the concentration in the normal plasma control.
The high concentration of protein C allowed the amidolytic activity to be assayed directly
in whey. This contrasted sharply with the necessity to use a capture method to
concentrate protein C prior to amidolytic activity of whey samples from mice transgenic
for the 2.4 kb WAP promoter fragment.
The amidolytic activity of protein C in the whey sample was also compared with the
activity of purified human protein C diluted in whey. At comparable concentrations of
protein C, amidolytic activity in transgenic mouse whey was nearly the same as that of
human protein C.
TABLE 5
Detection of human protein C in the milk of transgenic mice having
the 5' 4.2 kb WAP-promoter-9.4 kb human genomic protein C
construct stably integrated in their genomes
PC ANTIGEN
TRANSPC ANTIGEN
BY POLYAMIDOLYTIC
MOUSE
GENE
BY 12A8CLONAL
ACTIVITY IN
NUMCOPY
MAB ELISA
ELISA
WHEY (% N-

BER
5.4
6.4
4.2.10
5.2.12
7.2.2
7.5.4

NUMBER
14
10
10
20
2
30

(mg/ml)
0.05 .+-. -0.01
1.00 .+-. -0.03
1.69 .+-. -0.09
0.96 .+-. -0.09
0.33 .+-. -0.03
0.96 .+-. -0.04

(mg/ml)
0.14 .+-.
2.94 .+-.
3.98 .+-.
2.50 .+-.
0.89 .+-.
1.99 .+-.

PLASMA)
-0.01
N.D.
-0.09
56.2
-0.09
54.8
-0.10
54.9
-0.14
N.D.
-0.33
18.8

Finally, some of the transgenic mice were sacrificed and examined to determine the tissue
specificity of expression of human protein C. RNA blots and immuno in situ histological
examination showed that at least 99% of the protein C expression occurred in the
mammary glands in these animals. These results contrast with the results achieved using
whey acidic protein promoter constructs that contained only the 2.4 kb promoter
fragment. Constructs using this promoter to drive protein expression in transgenic mice
engendered expression that differed from the normal pattern of whey acidic protein
expression during development and in adult tissues. In fact, this was true for the whey
acidic protein itself. Thus, in addition to providing high levels of expression of a protein,
the 4.2 kb 5' WAP promoter fragment also provides greater tissue specificity of
expression in the adult mouse.
(D) Purification of Protein C from Transgenic Mouse Whey
Human protein C was partially purified from transgenic mouse whey by immunoaffmity
chromatography using the 12A8 monoclonal antibody immobilized on a Sepharose
support. Bound protein C was eluted in 0.1 M glycine, 0.02 M histidine, 0.15 M NaCl pH
10. Transgenic protein C purified in this manner revealed essentially the same banding
pattern upon SDS-PAGE as a standard preparation of purified human protein C.
EXAMPLE 12
Preparation of DNA Constructs Containing a Mouse Long Whey Acid Protein Promoter
Fragment and a Factor IX DNA for Expression in Transgenic Animals
Generally, the entire murine WAP gene was cloned by standard methods, as described
above. Generally, the entire murine WAP gene including 2.5 kb of 5' untranslated
sequence and 3' untranslated regions was cloned by standard methods. See Campbell et
al., Nucleic Acids Res. 12:8685 (1984). A cDNA fragment encoding human Factor IX
was obtained and the 3' untranslated region was deleted. Using standard methods, an
expression vector was constructed that contained a mouse WAP promoter, isolated as a
2.6 kb EcoRI-KpnI fragment immediately 5' to the WAP signal sequence, the human
Factor IX cDNA sequence lacking a 3' untranslated region, and a 1.6 kb fragment of the
3' untranslated region of the WAP gene. A second expression vector contained a 7.2 kb
mouse WAP gene (EcoRI-EcoRI) fragment. Expression vectors were amplified by
bacterial transformation and purified from bacterial cultures using standard methods.
Routine recombinant DNA techniques can be found, for example, in Sambrook et al.,
MOLECULAR CLONING, A LABORATORY MANUAL, Vol. 1-3 (Cold Spring
Harbor Press 1989). More specifically, a chimeric Factor IX construct was prepared, as

follows:
(A) Preparation of a Chimeric Factor IX Construct
1. Production of pWAP4 "Cassette Vector"
Regulatory 5' and 3' flanking sequences of the mouse WAP gene were used for mammary
specific expression. Specifically, a cassette vector containing a mouse WAP promoter,
defined as a 2.6. kb EcoRI-KpnI fragment immediately 5' to the WAP signal sequence
and a 1.5 kb fragment of the 3' untranslated region of the WAP gene was prepared. These
regulatory sequences do not include coding and intragenic untranslated sequences
(introns) of the WAP gene.
The vector designated pWAP4 was derived from pWAPPC3 (C. Russell, dissertation
"Improvement of Expression of Recombinant Human Protein C in the Milk of Transgenic
Mammal Using a Novel Transgenic Construct," Virginia Technology Institute,
Blacksburg, Va. (December 1993)) and was developed as follows: Using WAPPC3 as a
template, PCR primers WAP3'S2 (which contains a 5'KpnI site and is homologous to
endogenous WAP right after the stop signal) and WAP3'A1, as shown in Table 6, below,
were used to produce a segment with KpnIl and BamHI sites on either end. This segment
was digested with KpnI/BamHI and ligated with the vector containing the fragment from
KpnI/BamHI digested pWAPPC3. The ligation mixture was used to transform E. Coli
DH5.alpha. cells by electroporation with resultant colonies grown on LB ampicillin
plates. Picked colonies were grown up in TB ampicillin broth, plasmids isolated and cut
with KpnI, BamHI or both and subjected to gel electrophoresis. Sequencing was
performed using WAP3'A1 primer and judged as being correct. See FIG. 10A.
TABLE 6
Primer Sequences
SEQ ID NO: 2
humFIX5'KpnI
5'gcta.backslash.ggtacc.backslash.atgcagcgcg
SEQ ID NO: 3
humFIX3'KpnI
5'gtca.backslash.ggtacc.backslash.ttaagtgagct
SEQ ID NO: 4
FIXS1
5'ggataacatcactcaaagcac
SEQ ID NO:5
WAP3'A1
5'tagcagcagattgaaagcattatg
SEQ ID NO: 6
FIXA1
5'gtgaactttgtagatc

2. Production of Modified (Kpn I) FIX cDNA
The FIX cDNA (containing Kpn I sites located immediately before the start sequence and
after the stop sequence) was generated as a PCR fragment. Fragment production protocol
is as follows: 100 .mu.l total volume containing 200 .mu.M dNTP's, 0.5 .mu.M of each
primer (humFIX5'KpnI and humFIX3'KpnI, as shown in Table 6), 2.5 units Pfu

polymerase and 30 ng of plasmid template (pMCDSFIX obtained from Prof. Darryl
Stafford, Department of Biology, University of North Carolina, Chapel Hill, N.C., USA),
reaction mixture was subjected to 30 cycles of denaturation at 95.degree. C. for 20 sec,
annealing at 50.degree. C. for 1 min and elongation at 75.degree. C. for 5 min 45 sec.
After cycling, the reaction mixture was subjected to blunting with T4 DNA polymerase
for 10 min, EDTA concentration brought up to 25 mM, heated to 65.degree. C. for 15
min, and extracted with Phenol: Chloroform (1:1), precipitated with equal volumes of
95% ethanol, aspirated, and suspended in H.sub.2 O.
3. Ligation, Transformation and Sequencing
As is shown in FIG. 10B, the plasmid designated pUCFIX containing the modified (Kpn
I ends) FIX cDNA was produced by digestion of both pUC18 and the modified cDNA
with Kpn I (per manufacturers instructions, Stratagene, La Jolla, Calif.) purification of
digestion products by CHCl.sub.3 : Phenol (1:1) extraction, precipitation with equal
volumes of 95% ethanol, aspiration and suspension in H.sub.2 O. Ligation of plasmid and
cDNA was per manufacturers instructions (Stratagene) using 125 ng of Kpn I digested
pUC18 and 125 ng of Kpn I digested modified cDNA. E. coli JM109 was transformed by
electroportation using ligation mixture and plated on LB ampicillin plates. Selected
colonies were grown up in TB ampicillin broth. Plasmid preparations from these colonies
were analyzed by restriction enzyme digestion (Kpn I) and gel electrophoresis. The entire
sense strand of the cDNA was sequenced and found to be correct as compared with FIXA
sequences located in GenBank.
4. Introduction of FIX cDNA into pWAP4 "cassette vector" to produce pWAPFIX
As shown in FIG. 10C, both pWAP4 and pUCFIX were digested with Kpn I in separate
reactions, subjected to gel electrophoresis and the appropriate plasmid fragments
removed from the gel and ligated. E. coli JM109 was transformed by electroportation
using ligation mixture and plated on LB ampicillin plates. Selected colonies were grown
up in TB ampicillin broth. Plasmid preparations from these colonies were analyzed by
restriction enzyme digestion (Kpn I) then gel electrophoresis. Clones positive for the
insert were subjected to PCR analysis using primers FIXS1 and WAP3'A1 to determine
the correct orientation of the insert.
As shown in FIG. 10D, the insert containing WAP promoter, cDNA and 3'WAP UTR
was released from pWAPFIX by EcoRI digestion, subjected to gel electrophoresis,
removed from the gel and purified. This fragment was ligated with Kpn I digested pUC18
and the reaction mixture used to transform E.coli JM109 by electroportation. After
electroportation, cells were plated on LB ampicillin plates with picked colonies grown in
TB ampicillin broth. Plasmids from picked colonies were purified and subjected to EcoRI
enzyme digestion and electrophoresis. After insert confirmation, large scale purification
was undertaken, according to methods well known to the skilled artisan.
(B) Production of Constructs Containing the Long WAP Promoter

Specifically, a cassette vector containing a mouse long WAP promoter, defined as a 4.1
kb NotI-Kpn1 fragment immediately 5' to the WAP signal sequence and a 1.6 kb
fragment of the 3' untranslated region of the WAPgene was prepared. These regulatory
sequences do not include coding and intragenic untranslated sequences (introns) of the
WAP gene.
The vector designated pUCWAP6 was derived from genetic elements from the following
plasmids as starting material: pUC18, pWAP4 and p227.6, which were provided by the
American Red Cross. The development of pUCWAP6 is as follows: The pUC18 vector
was cut with the enzymes EcoRI and Hind III to remove the multiple cloning site of the
vector, blunted with exonuclease and ligated with NotI linkers. The linerarized plasmid
was then cut with NotI and ligated. Ligation mixture was used to transform E. coli
DH5.alpha. cells on LB ampicillin plates, picked colonies were grown in TB ampicillin
broth, plasmids were isolated and cut with NotI then subjected to gel electrophoresis. A
plasmid was judged to be correct and designated as pUCNotI (See FIG. 11A). The vector
pWAP4 as described above and as described in U.S. Ser. Nos. 08/198,068 and
08/443,184, was cut with EcoRI and the fragment containing the WAP 5' 2.6 kbp and 3'
genetic elements were separated by gel electrophoresis and purified. The ends of the
fragment were modified by blunting with exonuclease and NotI linkers were ligated on.
The fragment was cut with NotI and ligated into the NotI restriction site of pUCNotI then
used to transform E. coli DH5.alpha. cells on ampicllin plates picked colonies were
grown in TB ampicillin broth. Isolated plasmid was verified to be correct by NotI
digestion with the plasmid being designated pUCWAP5. The pUC WAP5 plasmid was
subjected to KpnI digestion and a partial NotI digestion producing a fragment that
contained the pUCNotI vector sequence flanked by the mWAP 3'UTR (See FIG. 11B).
This fragment was ligated with the 4.1 kb 5' WAP promoter produced from digestion of
p227.6 with NotI, KpnI and Hind III. The ligation mixture was then used to transform E.
coli JM109 cells that were grown on LB ampicillin plates picked colonies were grown in
TB ampicillin broth, plasmids isolated were cut with NotI, and NotI/KpnI and judged to
be correct. The plasmid was then designated pUCWAP6 (See FIG. 11C).
As shown in FIG. 12, the plasmid pUCWAP6FIX was produced by digestion of
pUCWAPFIX with KpnI and isolating the FIX cDNA by gel electrophoresis. This
fragment was inserted into the KpnI site of pUCWAP6 after KpnI digestion and both
fragments were then subjected to ligation. The ligation mixture was then used to
transform E. coli JM109 cells that were then plated on LB ampicillin plates. Picked
colonics were grown in TB ampicillin broth and plasmids were isolated. Isolated
plasmids were digested with NsiI to verify orientation of the cDNA insert. Plasmids that
contained the insert in the correct orientation were designated pUCWAP6FIX. After inert
confirmation, large scale purification was undertaken, according to methods well known
to the skilled artisan. DNA was prepared for microinjection and injected into animals as
described above and as is known by persons skilled in the art. Analysis of Factor IX
DNA derived from the tissue of the transgenic animals and the analysis of the Factor IX
produced in the transgenic animals are performed by methods well known to persons
skilled in the art and as described in PCT/US98/02638, a continuation-in-part of
provisional U.S. Pat. No. 60/037,145, which are both incorporated in their entirety by

reference. Factor IX was expressed in transgenic animals made from the constructs
described in the present invention.
EXAMPLE 13
Construction of Expression Vectors Containing a Long Mouse Whey Acid Protein
Promoter Fragment and Fibrinogen (FIB) DNA for Expression in Transgenic Animals
(A) Construction of Cassette Vectors
FIB subunit chain DNAs, tissue-specific promoters, and secretion signal sequences were
obtained from sources described above. FIB subunit chain cDNAs were cloned into a
modified pUC 18 vector, and grown up in E. coli JM109.
A pUC18 vector (GIBCO-BRL, Gaithersburg, Md.) was digested with HindIII+ EcoRi
restriction endonucleases, blunted with T4 DNA polymerase in the presence of 100 mM
dNTPs, and a Not I linker was ligated into the former HindIII-EcoRI multiple cloning
site. This modified pUC fragment was additionally digested with Not I+ enzyme to
remove extra (multiple copies) Notd linker sequences arising from ligation, and then
religated and grown up in E. coli JM 109. This procedure modified the pUC18 vector by
removing the entire multiple cloning region of pUC18 (including the Kpn I site) and
replacing it with a Not I restriction site. The new vector was designated pUCNot1 +.
A pUC vector containing .sup..about. 2.6 kbp of WAP 5' promoter region, .sup..about.
1.3 kbp of WAP 3' UTR and flanking 3', but no WAP coding or intronic regions was
constructed (designated cassette vector pUCWAP4, as described in Example 12 and as
shown in FIG. 11A). The WAP fragment contained within the WAP4 vector contains a
.sup..about. 2.6 kbp WAP promoter 5' region beginning at EcoRI#1 and ending at the
translational start site of WAP which is immediately downstream of the unique Kpn I
endonuclease restriction site. To this KpnI site was ligated a fragment of .sup..about. 1.3
kbp of WAP UTR and flanking 3' sequence. This WAP 3' DNA included the region from
immediately downstream of the WAP stop codon down to the EcoRI#2 site. The WAP
fragment contained in WAP4 was excised from the pUC vector using EcoRI, and then
blunted, and NotI linkers were added, further trimmed by NotI digestion, and ligated into
the pUCNotI+ plasmid which had been linearized with NotI restriction endonuclease. The
resulting plasmid was designated pUCWAP5 (see FIG. 13).
(2) Amplification by PCR of Fibrinogen Subunit Chain cDNAs
The DNA sequences encoding the A.alpha., B.beta., and .gamma. chains for human
fibrinogen (hFIB) are known and disclosed. Fibrinogen cDNA sequences encoding the
human fibrinogen A.alpha., B.beta., and .gamma. chains are known and published. See,
e.g. Rixon et al., Biochemistry 22, 3237-3244 (1983), Chung et al., Biocehmistry 22,
3244-3250 (1983) and Chung et al., Biocehmistry 22, 3250-3256 (1983). The genomic
DNA sequences encoding the human fibrinogen A.alpha., B.beta., and .gamma. chains
are known and published. See, e.g. Chung et al., Adv. Exp. Med. Biol. 281, 39-48 (1990).

Each of the cDNAs for A.alpha., B.beta., and .gamma. chains for human fibrinogen were
individually modified and amplified by polymerase chain reaction (PCR) to create KpnI
endonuclease restriction sites on their 5' and 3' ends. The 5' KpnI site was engineered by
PCR using the primers [containing the 6 base sequence (GGTACC shown underlined in
Table 7)] that immediately flanks the ATG start codon in the cDNAs of A.alpha., B.beta.,
and .gamma. chains for hFIB. After amplification, the ends of the extension using PCR
products were blunted by T4-polymerase (in the presence of
deoxynucleosidetriphosphates to inhibit processive exonuclease activity. In a similar
fashion, a KpnI site was engineered by site modification into the 6 base sequence
GGTACC shown underlined in Table 7 immediately flanking the stop sequence in the 3'
UTR of each cDNA for A.alpha., B.beta., and .gamma. chains for hFIB. The complement
of the stop sequences is shown in bold in the 3' primers in Table 7.
TABLE 7
Oligonucleotides for Amplifying FIB
Subunit Chain cDNA
Seq. ID No: 7
A.alpha. 5' GCTAGGTACCATGTTTTCCATGAGGATCGT
Seq. ID No: 8
A.alpha. 3' CAGTGGTACCCTAGACAGGGCGAGATTTAG
Seq. ID No: 9
B.beta. 5' GCTAGGTACCATGAAAAGAATGGTTTCGTG
Seq. ID No: 10
B.beta. 3' CAGTGGTACCCTATTGCTGTGGGAAGAAGG
Seq. ID No: 11
.gamma.5' GCTAGGTACCATGAGTTGGTCCTTGCACCC
Seq. ID No: 12
G.gamma.3' CAGTGGTACCTTAAACGTCTCCAGCCTGTT
GGTACC = KpnI site
ATG = start codon
CTA and TTA = stop codon

(C) Construction of pUC Plasmids Containing Fibrinogen Subunit Chain cDNA
The blunted PCR products of the cDNAs for the B.beta. and .gamma. chains of hFIB
were digested with KpnI restriction endonuclease. In the case of the A.alpha. chain, the
PCR product was blunt-end cloned into pUCNotI+ (which had been digested with NotI
and blunted with T4 Polymerase) prior to partial KpnI digestion. This intermediate
cloning and partial digestion step was necessary to generate intact coding fragment due to
the presence of an internal KpnI site within the A.alpha. chain cDNA. The intact A.alpha.
chain cDNA fragment was selected by gel electrophoresis, and cloned into the KpnI site
at the junction between the WAP 5' promoter and WAP 3' UTR/flanking sequences
within the pUCWAP5 plasmid. The KpnI-digested PCR products from B.beta. and
G.gamma. chains for human fibrinogen were each directly cloned into a pUCWAP5
plasmid at the KpnI site. Separate electroporation transformation reactions were done on
E. coli using each of the three pUCWAP5/fibrinogen cDNA preparations, and colonies
were picked and grown up in TB ampicillin broth. Plasmid preparations from these
colonies were analyzed by restriction enzyme digestion and gel electrophoresis. The
correct size and orientations were selected and one clone for each WAP-fibrinogen

cDNA construct was sequenced at the WAP promoter 5':fibrinogen cDNA and fibrinogen
cDNA:WAP 3' UTR and flanking junctions. Schematics summarizing the construction of
the WAP-A.alpha. (about 5.8 kbp), -B.beta. (about 5.4 kbp), and -.gamma. (about 5.2
kbp) cDNA plasmid and linearized transgenes for human fibrinogen are given in FIGS.
14, 15, and 16, respectively.
Each of the pUCWAP5-A.alpha., pUCWAP5-B.beta. and pUCWAP5-.gamma. are
digested with KpnI and the DNA fragments encoding the A.alpha., B.beta., and .gamma.
chains were isolated by gel electrophoresis. The plasmid pUCWAP6 as shown in FIG.
11C was digested with KpnI as shown in FIG. 12 for the preparation of Factor IX long
WAP constructs. Each of the fragments encoding the A.alpha., B.beta., and .gamma.
chains was inserted into the KpnI site of pUCWAP6 after KpnI digestion and both
fragments were then subjected to ligation. The ligation mixture was then used to
transform E. coli JM109 cells that were then plated on LB ampicillin plates. Picked
colonics were grown in TB ampicillin broth and plasmids were isolated. Isolated
plasmids were digested with NsiI to verify orientation of the cDNA insert. Plasmids that
contained the insert in the correct orientation were designated pUCWAP6-A.alpha., B.beta. and .gamma., respectively. After inert confirmation, large scale purification was
undertaken, according to methods well known to the skilled artisan. DNA was prepared
for microinjection and injected into animals as described above and as is known by
persons skilled in the art. Analysis of hFIB DNA derived from the tissue of the transgenic
animals and the analysis of the hFIB produced in the transgenic animals are performed by
methods well known to persons skilled in the art and as described in U.S. Ser. Nos.
08/443,184 and 08/198,068, which are both incorporated in their entirety by reference.
The expression of fibrinogen in transgenic animals made from some of the constructs
described in the present application is disclosed in Butler et al., Thrombosis and
Haemostasis, 78(1) 537-542 (1997).
Although the foregoing refers to particular preferred embodiments, it will be understood
that the present invention is not so limited. It will occur to those of ordinary skill in the
art that various modifications may be made to the disclosed embodiments and that such
modifications are intended to be within the scope of the present invention, which is
defined by the following claims.
All publications and patent applications mentioned in this specification are indicative of
the level of skill of those in the art to which the invention pertains. All publications and
patent applications are herein incorporated by reference to the same extent as if each
individual publication or patent application were specifically and individually indicated
to be incorporated by reference in its entirety.
<100>
<160>
<200>
<210>
<211>
<212>

SEQUENCE LISTING
GENERAL INFORMATION:
NUMBER OF SEQ ID NOS: 12
SEQUENCE CHARACTERISTICS:
SEQ ID NO 1
LENGTH: 4122
TYPE: DNA

<213> ORGANISM: WAP gene promoter fragment from the C57B/6 mouse
strain
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (544)..(544)
<223> OTHER INFORMATION: "n" is unknown
<400> SEQUENCE: 1
gatctctcca tctaaggacc agccatgagc cattgagcag ccacagaaaa catttactat
60
ttatttatct atttattata tttaaataaa cataaaatat aaacatatca atgttgttaa
120
tgttttattc atgtgtattt gttaatattt ataacttact aatatttatt aagacttgtc
180
tctgtgtgtg tgtgtgtgca tgtgtgtgtg catgtgtgag gtatacatgt gtatacaggt
240
gcataaagag agcgagagct ttgttctaga gttggaacta caggtagttg tgaggcaaca
300
gatttgaatc ctggagacaa acttggtcct ctacaagatc accaagtaat ctttacaact
360
gagccatctt tccaggccct gaagataatt tttaatggaa tagggggact aataattttt
420
caaagatttt atttatttgc attttatcgg ttctgaatat tttacctgca tgtaagtgcc
480
acaaaagact agaaggagga ggcaggtcct agaactggac ctagggccat cctcggctac
540
tatntgggct ctgggaatct agcctgcatc ttcagcaaga gcaacaagtg ctcttaacct
600
gttgacccat gtgtgtttat gtatcaagca cagtgagctg cttctgtaga gggtggccaa
660
ggcctgaaca ttctcagcag actggaacac ctaacccaat ctctacttga gggaaaactc
720
agggactcct cccaggcatc tcctctcaga cccaaggttg agcccaggag ctccttgccc
780
tgtgcctaag gagtggtaga aagaggaagt gtgggcccct tttccaaggt ggggatcaac
840
ttgatgctct gacccctact gtccttcaag atccacaaac actgtaaagg gtttcctggg
900
tacctctaaa tcacagcatg actgaaaaaa atccccctag actgtaaagg gtttcctggg
960
cctgtttaga aaccacttct ctatcacctg ctaattctcc acagtccctg ttccaatgga
1020
gaccctcctg gcaggtttct gaaggaggga gtagcaggtc aaacttctcc tctcatcaga
1080
ggagaggcca ggccctcctc cttctcacca aaggggctca acacctcacc ccttctcagc
1140
acttctgcct tctcacttaa acatggtgac cccagactct gtgccaacaa tcactccctc
1200
ctgggggcac ctctggaggc tgcaccccgt ccgctggacc caacacagat gggctagcta
1260
acgagccaca agggaacatg ccagagccac atagtgcagt agagcagcca tgcagctcgt
1320
acctccttgc tgttgcttag agcagccggt gccagctggg gtgtctaaca caattaccct
1380
tggtgctgct gagcagggga caggccaagg agctttgggg aaggagacac actgtatacg
1440
gatatgactg aggcatatga ggggtgtagg agagcctcag aatgagcagc aaggcctatg
1500

actaaggtct gacatagcac agtgacaagg atgacatgta gtcgtgactt cactgaagag
1560
ggagagactc tcactcagaa ttcctaagca ccatggccaa gaatggggca agctgttcat
1620
ccaggagcca taaagcacta caagaaagaa gcaagctcgt ggggcaggca gcctgtcctc
1680
ctccatcacc ctgtcctcct cttccaccct gtccactgct caggttttta gggaaaattc
1740
cagcacagct gaccccatag gacaaaaagt gcagtgtgtg tactaccaaa accctgggtg
1800
tccttttccc accctagccg agcagagttg atggggcagg aaagagccta gcatactgga
1860
agcacacagg ctcaagactg gcaggccaaa gaaccagaac accccagggc ataagaaccc
1920
catgcccctt gccgctgggc ctggtgaatt cagagtaatg tcttcattcc tagaaccttc
1980
tggcttcccg acctggcctg caggctctga gagatgtgtg cacctcatga actccttgtt
2040
cagccagggc ctctctgtcc tccctacact tccccaccac acaggaacac atgtcctcaa
2100
ctgaccagtg tcaccctggg cctcaaggct aggttccctt gagtactggg aacacaagaa
2160
tagacttctg ctctcccctc tgtccacaca gagtgcagag agcaagggtt ctggttcatg
2220
tcccacagtt gccccctaaa accgatgtga tatagccctc actggcctag agctcactac
2280
ataaacaggc tggcctgaac ccacagatct gtctgccttt gactcctact gctgggatca
2340
aaggtgtgag ccaccatgca acgctctgaa actgattctt tagaagctaa gaaaatgctt
2400
caaaatggca gtagccttgg cgtggagatg ggttagtggt taagagaact gactgctctt
2460
ccagagagag agagagagag agagagagag agagagagag agagagagag agctggaaga
2520
gggagatctg ggaagtctgc tggctttata tgctgaccat atatagtcac ctgtgtttac
2580
aactgttgct catcactttg aaatctcagt ggtttcctcc tttgagcctg tgtctgtaag
2640
ttacacagga cagtggtact ataggcaaga ataacagcca gtgggcatag gacacagagt
2700
gcatgggccc cagcaagatg cagagagaac agagctctgg ctcctaagac acagggcctt
2760
ctgggaaact caagcagcca agcaacccta gccagccctt tcctggtggc cctccttctg
2820
ttccagcaaa ggcggaaatg ggaacagggg tggaagcaga gcattggcag agcataggta
2880
tgacttagtc ttgactaaca caagcatggc agtagcctga cagtggccta aatgtgggga
2940
tgactgcctt agatgaggat gactgcctta gatggggatg actgccttag atggggatga
3000
ctgccttaga tggggatgac tgccttagat ggaacaacaa acatctatgg gcatgctgtg
3060
gaacactggc ccacacacgg aactgaagca ctggcaattt ccacagggca gttaaaccta
3120
aaagcatgct cacactcaac aggctgccgg aactcatgag acacctggaa tagacgaatg
3180

tagaaacaga gcagagagtt ggttgccaag gtctgggggc tcagaggaca agcaagaggc
3240
gcggctttcc tttggggctg gcatgaaagg aaatatcgag gttacagcct gagagggctt
3300
cccctgacac ttcgtattca aagaggccat gggcaccagt gaagacaaag gagtatggcc
3360
tgcaccacag gctggcnctg acagtcagta agcacacagt cactctgggt catcccatcc
3420
ccttccttgc aagagaaatc aaggaaatgt cccgagaaca atggggcaca gtgccagcag
3480
gacatctctt cctgcccaat gacacccttg gcacagtatg ggcccttctg ggaagttggc
3540
cttccaatgt gctctgcaca ggcagctcct tttcaatgta tgcccgacac tctctacatg
3600
gagcaagcgc ctccacactc ttagaagaat ttttagaaaa ctccagaaaa gcaccaggag
3660
aagtcaccct cagatgtagc ccggactcga gccttgctca aaacctcctg tcttgttttc
3720
tatgtgactg tacaaatttg gagctcagaa ttgcctttgt ctgtgatggg ttccaaccca
3780
accactcaaa gtgacacttg tcacatttgt cactgatcct atttcttctt tttctgctcc
3840
ttcattttct ccgctttcat aataaacaag tattactttt taagtggggg aaaaaatgac
3900
cacccttaca aaggactttt taaaaatggc ctccattgtg gcccttgttc ctggcagcct
3960
gggcctgctc tctctgtgtg gccaagaagg aagtgttgta gcccatctag agctgtgcca
4020
gcctcttccc ccaccccacc cccaaagtct tcctcctgtg ggtcctttaa atgcatccca
4080
gacactcaga cagccatcag tcacttgcct gacaccggta cc
4122
<200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 2
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: primer
<400> SEQUENCE: 2
gctaggtacc atgcagcgcg
20
<200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 3
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: primer
<400> SEQUENCE: 3
gtcaggtacc ttaagtgagc t
21
<200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 4
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: primer
<400> SEQUENCE: 4
ggataacatc actcaaagca c
21
<200> SEQUENCE CHARACTERISTICS:

<210> SEQ ID NO 5
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: primer
<400> SEQUENCE: 5
tagcagcaga ttgaaagcat tatg
24
<200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 6
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: primer
<400> SEQUENCE: 6
gtgaactttg tagatc
16
<200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 7
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: primer
<400> SEQUENCE: 7
gctaggtacc atgttttcca tgaggatcgt
30
<200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 8
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: primer
<400> SEQUENCE: 8
cagtggtacc ctagacaggg cgagatttag
30
<200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 9
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: primer
<400> SEQUENCE: 9
gctaggtacc atgaaaagaa tggtttcgtg
30
<200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 10
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: primer
<400> SEQUENCE: 10
cagtggtacc ctattgctgt gggaagaagg
30
<200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 11
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: primer
<400> SEQUENCE: 11
gctaggtacc atgagttggt ccttgcaccc
30
<200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 12

<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: primer
<400> SEQUENCE: 12
cagtggtacc ttaaacgtct ccagcctgtt
30

